<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Tookad 4182 - En Annexes (clean) - FINAL</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ZapfDingbats;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\(Utiliser une police de caractè";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:+mn-ea;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:inherit;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-link:"List Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{mso-style-link:"List Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{mso-style-link:"List Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{mso-style-link:"List Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.CorpsdeTexte, li.CorpsdeTexte, div.CorpsdeTexte
	{mso-style-name:"Corps de Texte";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
p.No-numheading5Agency, li.No-numheading5Agency, div.No-numheading5Agency
	{mso-style-name:"No-num heading 5 \(Agency\)";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.ListParagraphChar
	{mso-style-name:"List Paragraph Char";
	mso-style-link:"List Paragraph";
	font-family:"Times New Roman",serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img width=21
height=18 id="Image 1"
src="Tookad%204182%20-%20En%20Annexes%20(clean)%20-%20FINAL_files/image001.png"
alt="BT_1000x858px"></span><span lang=EN-GB>This medicinal product is subject
to additional monitoring. This will allow quick identification of new safety
information. Healthcare professionals are asked to report any suspected adverse
reactions. See section 4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.       NAME OF </span></b><b><span lang=EN-GB>THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD 183&nbsp;mg
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD 366&nbsp;mg
powder for solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><u><span lang=EN-GB>TOOKAD 183&nbsp;mg powder for solution
for injection</span></u></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>Each vial contains 183&nbsp;mg of
padeliporfin (as di-potassium salt).</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><u><span lang=EN-GB>TOOKAD 366&nbsp;mg powder for solution
for injection</span></u></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>Each vial contains 366&nbsp;mg of
padeliporfin (as di-potassium salt).</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>1 mL of reconstituted solution contains
9.15&nbsp;mg of padeliporfin.</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder for
solution for injection. The powder is a dark lyophilisate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.       </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>TOOKAD is indicated as monotherapy for
adult patients with previously untreated, unilateral, low&#8209;risk,
adenocarcinoma of the prostate with a life expectancy &#8805;&nbsp;10 years
and:</span></p>

<p class=MsoNormal><span lang=EN-GB>-        Clinical stage T1c or T2a, </span></p>

<p class=MsoNormal><span lang=EN-GB>-        Gleason Score &#8804;&nbsp;6,
based on high-resolution biopsy strategies, </span></p>

<p class=MsoNormal><span lang=EN-GB>-        PSA&nbsp;&#8804;&nbsp;10 ng/mL, </span></p>

<p class=MsoNormal><span lang=EN-GB>-        3 positive cancer cores with a
maximum cancer core length of 5 mm in any one core or 1 -2 positive cancer
cores with &#8805;&nbsp;50&nbsp;% cancer involvement in any one core or a PSA
density&nbsp;&#8805;&nbsp;0.15 ng/mL/cm<sup>3</sup>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2     Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD is
restricted to hospital use only. It should only be used by personnel trained in
the Vascular-Targeted Photodynamic therapy (VTP)</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
posology of TOOKAD is one single dose of 3.66</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg/kg of padeliporfin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD is
administered as part of focal VTP. The VTP procedure is performed under general
anaesthetic after rectal preparation. Prophylactic antibiotics and
alpha-blockers may be prescribed at the physician’s discretion. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Retreatment of
the same lobe or sequential treatment of the contralateral lobe of the prostate
are not recommended (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available in patients with hepatic impairment. Exposure to padeliporfin is
expected to be increased and/or prolonged in patients with hepatic impairment.
No specific dosage recommendation can be given. TOOKAD should be used with
caution in patients with severe hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD is
contraindicated in patients who have been diagnosed with cholestasis (see
section</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is minimal
renal excretion of TOOKAD so no adjustment in dose is required in patients with
renal impairment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains potassium. This should be taken into consideration (see
section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No specific
posology adjustment is necessary in this population (see section 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
relevant use of TOOKAD in the paediatric population in the treatment of
low-risk localised prostate cancer.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD is for
intravenous use. For instructions on reconstitution of TOOKAD before
administration, see section</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Illumination
for photoactivation of TOOKAD</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The solution is
administered by intravenous injection over 10 minutes. Then the prostate is
illuminated immediately for 22</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>minutes</span><span lang=EN-GB> </span><span lang=EN-GB>15</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>seconds by laser light at 753</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>nm delivered via interstitial optical
fibres from a laser device at a power of 150</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mW/cm of fibre, delivering an energy of 200</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>J/cm.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Planning of
optical fibre positioning should be performed at the beginning of the procedure
using the treatment guidance software. During the procedure, the number and the
length of the optical fibres are selected depending on the shape and the size
of the prostate and the optical fibres are positioned transperineally into the
prostate gland under ultrasound guidance to achieve a Light Density Index (LDI)</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>&#8805;</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>1 in the targeted tissue. Treatment should not be undertaken in
patients where an LDI&nbsp;&#8805;&nbsp;1 cannot be achieved (see section</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>5.1).</span></p>

<p class=BodytextAgency style='margin-bottom:0in;text-align:justify;text-justify:
inter-ideograph;line-height:normal'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any previous prostatic
interventions where the internal urinary sphincter may have been damaged, including
trans-urethral resection of the prostate (TURP) for benign prostatic
hypertrophy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Current or prior
treatment for prostate cancer.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients who
have been diagnosed with cholestasis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Current
exacerbation of rectal inflammatory bowel disease (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any medical
condition that precludes the administration of a general anaesthetic or
invasive procedures.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.4       Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Tumour
localisation</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Before
treatment, the tumour must be accurately located and confirmed as unilateral using
</span><span lang=EN-GB>high&#8209;resolution biopsy strategies </span><span
lang=EN-GB>based on current best practice,</span><span lang=EN-GB> such as
multi­&#8209;parametric MRI&#8209;based strategies or template­&#8209;based
biopsy procedures.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Simultaneous
treatment of both prostate lobes was associated with an inferior outcome in
clinical trials and should not be performed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Insufficient
patients underwent retreatment of the ipsilateral lobe or sequential treatment
of the contralateral lobe to determine the efficacy and safety of a second
TOOKAD&#8209;VTP procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Follow-up
post TOOKAD&#8209;VTP</span></u></p>

<p class=MsoNormal style='line-height:normal'>There is limited biopsy data
beyond 2 years after TOOKAD treatment, so long-term efficacy has not been
determined. <span lang=EN-GB>Residual tumour has been found on follow-up biopsy
of the treated lobe at 12 and 24&nbsp;months, usually outside of the treated
volume, but occasionally within the area of necrosis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is limited
data on long-term outcomes and on potential consequences of post-TOOKAD local
scarring in case of disease progression.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At present
TOOKAD-VTP has been shown to defer the need for radical therapy and its
associated toxicity. Longer follow-up will be required to determine whether
TOOKAD-VTP will be curative in a proportion of patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=BodytextAgency style='text-align:justify;text-justify:inter-ideograph;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Following
TOOKAD VTP, patients should undergo digital rectal examination (DRE) and have
their serum PSA monitored, including an assessment of PSA dynamics (PSA
doubling time and PSA velocity). PSA should be tested every 3 months for first
2 years post VTP and every 6-months thereafter in order to assess PSA dynamics
(PSA Doubling Time (DT), PSA velocity). Digital Rectal Examination (DRE) is
recommended to be performed at least once a year and more often if clinically
justified.Routine biopsy is recommended at 2-4 years and 7 years post VTP, with
additional biopsies based on clinical/ PSA assessment. mpMRI may be used to
improve the decision making but not, at present, to replace biopsy. In case of
positive biopsies, patients who exceed the threshold for low risk disease
(i.e.&nbsp;have GS &gt;6, &gt;3 positive cores or any single core length
&gt;5mm) should receive a treatment recommendation for radical therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Radical
therapy post VTP procedure</span></u></p>

<p class=MsoNormal style='line-height:normal'>The safety and efficacy of
subsequent radical therapy (surgery or radiotherapy) is uncertain. <span
lang=EN-GB>Limited information is available regarding the safety and efficacy
of radical prostatectomy after TOOKAD&#8209;VTP. </span>In small surgical
series, there have been reports of T3 tumours, positive margins and impotence. In
the 24 months of the pivotal European Phase III study, no patients underwent
radical radiotherapy post TOOKAD-VTP.<i> </i></p>

<p class=MsoNormal style='line-height:normal'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Photosensitivity</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is a risk
of skin and eye photosensitivity with exposure to light post TOOKAD-VTP. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is important
that all patients follow the light precautions below for 48 hours
post-procedure to minimize the risk of damage to the skin and eyes. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients should
avoid exposure to direct sunlight (including through windows) and all bright
light sources, both indoors and outdoors. This includes sunbeds, bright
computer monitor screens and medical examination lights, such as
ophthalmoscopes, otoscopes and endoscopy equipment, for 48&nbsp;hours following
the VTP&nbsp;procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sunscreen creams
do not protect against near infra&#8209;red light and, therefore, do not
provide adequate protection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If the patient
reports discomfort to the skin or eyes during hospitalisation, reduce the level
of lighting and take extra care to shield the patient from artificial and
natural light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>First 12</span></u></i><u><span
lang=EN-GB>&nbsp;<i>hours after VTP</i>&nbsp;<i>procedure</i></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The patient
should wear protective goggles and be kept under medical surveillance for at
least 6&nbsp;hours in a room with dimmed light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The patient may
be discharged in the evening of the same day at the physician’s discretion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The patient must
stay in a dimmed light environment without any direct exposure of the skin and
the eyes to daylight. The patient may only use incandescent light bulbs with a
maximum power of 60&nbsp;watts or equivalent (i.e. 6&nbsp;watts for LED lights,
12&nbsp;watts for fluorescent low-energy lights).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The patient may
watch television from a distance of 2&nbsp;metres and, from 6&nbsp;hours
onwards, may use electronic devices such as smartphones, tablets and computers.
If the patient must go outdoors during daylight hours, he should wear
protective clothes and high protection goggles to shield his skin and eyes.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>12&#8209;48</span></u></i><u><span
lang=EN-GB>&nbsp;<i>hours after VTP</i>&nbsp;<i>procedure</i></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The patient may
go outdoors during daylight hours but only in shaded areas or when it is
overcast. He should wear dark clothes and take care when exposing hands and
face to the sun.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The patient can
return to normal activity and tolerate direct sunlight 48&nbsp;hours after the
procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No patients with
photosensitive dermatitis, skin conditions such as porphyria or a history of sensitivity
to sunlight have received TOOKAD in clinical studies. However, the short
duration of action of TOOKAD means that the risk of enhanced phototoxicity is
expected to be low provided these patients strictly follow the precautions
against light exposure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There could be
an additional risk of eye photosensitivity in patients who have received intra&#8209;occular
anti&#8209;VEGF therapy. Patients who have received prior VEGF therapy should
take particular care to protect the eyes from light for 48&nbsp;hours post
TOOKAD injection. Concomitant use of systemic VEGF inhibitors is not
recommended with TOOKAD.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>See section 4.5
for interactions with photosensitizing medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Erectile
dysfunction</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Erectile
dysfunction may occur even if radical prostatectomy is avoided. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Some degree of
erectile dysfunction is possible soon after the procedure and may last for more
than 6&nbsp;months (see section 4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Extraprostatic
necrosis</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There may be extraprostatic
necrosis in the peri&#8209;prostatic fat not associated with clinical symptoms.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excessive
extraprostatic necrosis occurred as a result of incorrect calibration of the
laser or placement of the light fibres (see section&nbsp;4.8). In consequence </span><span
lang=EN-GB>there is a potential risk of damage to adjacent structures, such as
the bladder and/or rectum, </span><span lang=EN-GB>and</span><span lang=EN-GB>
development of a recto&#8209;urethral or external f</span><span lang=EN-GB>istu</span><span
lang=EN-GB>la</span><span lang=EN-GB>. A urinary fistula has occurred in one
case due to incorrect fibre placement.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The equipment
should be carefully calibrated and use the treatment guidance software to
reduce the risk of </span><span lang=EN-GB>clinically significant
extraprostatic necrosis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Urinary
retention/urethral stricture</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with a
history of urethral stricture or with urinary flow problems may be at increased
risk of poor flow and urinary retention post the TOOKAD&#8209;VTP procedure. Urinary
retention immediately post procedure has been attributed to transient prostatic
oedema and generally only short term recatheterisation was required.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Poor urinary
flow due to urethral stricture developed some months post procedure. In certain
cases, the bulbar location suggested that the stenosis was caused by urinary catheterisation.
In other cases, urethral stenosis may have been a late consequence of TOOKAD&#8209;VTP
induced necrosis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Although they
were excluded from the clinical trials, there is a potential risk of increased stenosis
post the TOOKAD&#8209;VTP procedure in patients with pre&#8209;existing
stenosis (see section 4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Urinary
incontinence</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The risk of
sphincter damage can be minimised by careful planning of the fibre placement
using the treatment guidance software. Severe long&#8209;term urinary
incontinence was observed in a patient who underwent a previous transurethral
prostatectomy (TURP).</span><span lang=EN-GB> This event was not considered to
be related to a faulty procedure but rather the pre&#8209;existing damage to
the internal urethral sphincter from the TURP.</span><span lang=EN-GB> The
TOOKAD&#8209;VTP&nbsp;procedure is contraindicated in patients with any previous
prostatic interventions where the internal urinary sphincter may have been
damaged, including transurethral resection of the prostate (TURP) for benign
prostatic hypertrophy (see section&nbsp;4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Inflammatory
bowel disease</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD&#8209;VTP
should only be administered after careful clinical evaluation, to patients with
a history of active rectal inflammatory bowel disease or any condition that may
increase the risk of recto&#8209;urethral fistula formation (see section 4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Use in
patients with abnormal clotting</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
abnormal clotting may develop excessive bleeding due to the insertion of the
needles required to position the light fibres. This may also cause bruising, haematuria
and/or local pain. It is not expected that a delay in clotting will reduce the
effectiveness of the TOOKAD&#8209;VTP treatment ; however, it is recommended
that drugs that affect clotting are stopped prior to and for the immediate
period following the VTP procedure (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Use in
patients on a controlled potassium diet</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains potassium and in general the dose (3.66&nbsp;mg/kg) will be
less than 1&nbsp;mmol (39&nbsp;mg) i.e. essentially ‘potassium free’. However,
this will be exceeded in patients heavier than 115&nbsp;kg. This should be
taken into consideration in patients with reduced kidney function or patients
on a controlled potassium diet where a rise in serum potassium would be considered
detrimental (see section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5     Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>OATP1B1 and OATP1B3
transporters</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> studies predict that TOOKAD at therapeutic concentrations is
unlikely to inhibit cytochrome P450 enzymes but could  inhibit OATP1B1 and
OATP1B3 transporters (see section 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The magnitude of
interaction has not been investigated clinically but a transient increase in the
plasma concentration of co&#8209;administered substrates of OATP1B1 and OATP1B3
cannot be ruled out. The use  of medicinal products that are substrates of
OATP1B1 or OATP1B3 (repaglinide, atorvastatin, pitavastatin, pravastatin,
rosuvastatin, simvastatin, bosentan, glyburide) for which concentration&#8209;dependent
serious adverse events have been observed should be avoided on the day of
TOOKAD infusion and for at least 24&nbsp;hours after administration. Co-administration
should be done with caution and close monitoring is recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Photosensitisers</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
products which have potential photosensitising effects (such as tetracyclines,
sulphonamides, quinolones, phenothiazines, sulfonylurea hypoglycaemic agents,
thiazide diuretics, griseofulvin or amiodarone) should be stopped at least 10&nbsp;days
before the procedure with TOOKAD and for at least 3&nbsp;days after the
procedure or replaced by other treatments without photosensitizing properties.
If it is not possible to stop a photosensitising medicinal product (such as
amiodarone), the patient should be advised that increased sensitivity to
sunlight may occur and they may need to protect themselves from direct light
exposure for a longer period (see section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Anticoagulants
and antiplatelet agents</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Anticoagulant
medicinal products and those that decrease platelet aggregation (e.g.
acetylsalicylic acid) should be stopped at least 10&nbsp;days before the
procedure with TOOKAD. Medicinal products that prevent or reduce platelet
aggregation should not be started for at least 3&nbsp;days after the procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6     </span></b><b><span lang=EN-GB>Fertility, p</span></b><b><span
lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Contraception</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If the patient
is sexually active with women who are capable of getting pregnant, he and/or
his partner should use an effective form of birth control to prevent getting
pregnant during a period of 90 days after the VTP&nbsp;procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pregnancy and
breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD is not
indicated for the treatment of women.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Padeliporfin has
not been tested for reproductive toxicity and fertility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>However, all
stages of spermatogenesis have been observed in animal. Minimal seminiferous
epithelial degeneration was also recorded in one high&#8209;dose male with
vacuolation. All these changes were considered to be incidental and probably
related to the intravenous administration procedure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7     Effects on ability to drive and use
machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD has no
influence on the ability to drive or use machines. However, as the procedure
includes general anaesthesia, patients should not perform complex tasks like
driving or using machines until 24&nbsp;hours after a general anaesthetic is
employed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.8     Undesirable
effects</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The most frequently reported adverse reactions in the Phase II and III
clinical studies were urinary and reproductive system disorders: dysuria (25.1&nbsp;%),
erectile dysfunction (21.1&nbsp;%), haematuria (19.6&nbsp;%), perineal
pain/haematoma (15.3&nbsp;%), urinary retention (13.3&nbsp;%), micturition
urgency (9.0&nbsp;%), pollakiuria (7.3&nbsp;%), urinary tract infection (5.5&nbsp;%),
incontinence (5.3&nbsp;%) and ejaculation failure (5.0&nbsp;%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Unspecific
adverse events probably linked to the general anaesthesia were also observed: </span><span
lang=EN-GB>transient global amnesia, bradycardia, sinus arrhythmia, atrial
fibrillation, hypotension, bronchospasm, pharyngeal inflammation, respiratory
tract congestion, nausea, vomiting, constipation, pyrexia, procedural hypotension.
Some cases of hepatotoxicity (1.5&nbsp;%), such as elevation of transaminases,
were also reported. All of them were mild in intensity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Tab<span
style='letter-spacing:.05pt'>u</span>lated<span style='letter-spacing:-.45pt'> </span>list<span
style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>o</span>f<span
style='letter-spacing:-.1pt'> </span>adverse<span style='letter-spacing:-.35pt'>
</span>rea<span style='letter-spacing:-.05pt'>c</span>ti<span style='letter-spacing:
.05pt'>o</span>ns</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adverse
reactions reported are listed below in Table&nbsp;1 by organ class and
frequency. </span><span lang=EN-GB>Within each frequency grouping, adverse
reactions are presented in order of decreasing seriousness</span><span
lang=EN-GB>. Frequencies are defined as: very common (&#8805;&nbsp;1/10);
common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000
to &lt;&nbsp;1/100).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Ta<span style='letter-spacing:.05pt'>b</span>le<span
style='letter-spacing:-.25pt'> </span>1:<span style='letter-spacing:-.1pt'> </span>S<span
style='letter-spacing:-.05pt'>u</span>m<span style='letter-spacing:-.05pt'>m</span>ary<span
style='letter-spacing:-.4pt'> </span><span style='letter-spacing:.05pt'>o</span>f<span
style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>a</span>d<span
style='letter-spacing:.05pt'>v</span>er<span style='letter-spacing:-.05pt'>s</span>e<span
style='letter-spacing:-.35pt'> </span><span style='letter-spacing:.05pt'>r</span>eacti<span
style='letter-spacing:.05pt'>o</span>ns<span style='letter-spacing:-.45pt'> </span>consider<span
style='letter-spacing:.05pt'>e</span>d<span style='letter-spacing:-.5pt'> </span>related<span
style='letter-spacing:-.35pt'> </span>to<span style='letter-spacing:.15pt'> </span>TOOK<span
style='letter-spacing:.05pt'>A</span>D<span style='letter-spacing:-.5pt'> </span>and/or<span
style='letter-spacing:-.3pt'> </span>the<span style='letter-spacing:-.15pt'> </span>s<span
style='letter-spacing:.1pt'>t</span>udy<span style='letter-spacing:-.2pt'> </span>de<span
style='letter-spacing:.05pt'>v</span>ice a<span style='letter-spacing:.05pt'>n</span>d/<span
style='letter-spacing:.05pt'>o</span>r<span style='letter-spacing:-.3pt'> </span>the<span
style='letter-spacing:-.15pt'> </span>stu<span style='letter-spacing:.05pt'>d</span>y<span
style='letter-spacing:-.2pt'> </span>procedure in the pooled safety analysis
(N=398)</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=200 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>System
   Organ Class</span></b></p>
   </td>
   <td width=131 valign=top style='width:98.3pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Frequency</span></b></p>
   </td>
   <td width=264 valign=top style='width:2.75in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Adverse
   reaction</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=200 rowspan=2 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Infections and
  infestations</span></p>
  </td>
  <td width=131 valign=top style='width:98.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Genito-urinary
  tract infection<sup>1</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=131 valign=top style='width:98.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Prostatic
  abscess</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=3 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Psychiatric disorders</span></p>
  </td>
  <td width=131 rowspan=3 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Libido decreased
   </span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Affective
  disorder</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Encopresis</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=5 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nervous system
  disorders</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=131 rowspan=5 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Headache<span
  style='background:lime'> </span></span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dizziness</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sciatica</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sensory
  disturbance</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Formication</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=2 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eye disorders</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=131 rowspan=2 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eye irritation</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Photophobia</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=2 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Vascular
  disorders</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=131 rowspan=2 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Haematoma</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypertension</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width=131 valign=top style='width:98.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Exertional
  dyspnoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=7 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=131 rowspan=4 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Haemorrhoids</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Anorectal
  discomfort<sup>2</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abdominal pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rectal
  haemorrhage<sup>3</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=3 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abdominal
  discomfort</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abnormal
  faeces</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Diarrhoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepatobiliary
  disorders</span></p>
  </td>
  <td width=131 valign=top style='width:98.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepatotoxicity<sup>4</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=7 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Skin and subcutaneous
  tissue disorders</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=131 valign=top style='width:98.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ecchymosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=6 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rash</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Erythema</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dry skin</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pruritus</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Skin
  depigmentation</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Skin reaction</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=6 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Muscular and
  connective tissue disorders</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=131 valign=top style='width:98.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Back pain<sup>5</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=5 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Groin pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Muscle haemorrhage</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Haemarthrosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Musculoskeletal
  pain </span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pain in
  extremity</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=9 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Renal and
  urinary disorders</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=131 rowspan=4 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Urinary
  retention</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Haematuria</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dysuria<sup>6</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Micturition
  disorders<sup>7</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=2 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Urethral
  stenosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Urinary
  incontinence<sup>8</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=3 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ureteric
  haemorrhage</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Urethral
  haemorrhage</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Urinary tract
  disorders</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=10 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reproductive
  system and breast disorders</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=131 rowspan=2 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Perineal pain<sup>9</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Male sexual
  dysfunction<sup>10</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=4 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Prostatitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Genital pain<sup>11</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Prostatic pain<sup>12</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Haematospermia</span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=4 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Genital
  haemorrhage</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Penile
  swelling<sup>13</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Prostatic
  haemorrhage</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Testicular
  swelling</span></p>
  </td>
 </tr>
 <tr style='height:.1in'>
  <td width=200 rowspan=8 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.1in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=131 valign=top style='width:98.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.1in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.1in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fatigue</span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=7 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Asthenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Catheter site
  pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Laser device failure</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Infusion site
  bruising</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nodule</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Application
  site erythema</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=12 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Investigations</span></p>
  </td>
  <td width=131 valign=top style='width:98.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abnormal
  clotting<sup>14</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=11 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Blood lactate
  dehydrogenase increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Blood
  triglyceride increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gamma-glutamyltransferase
  increased </span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Blood
  cholesterol increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Blood creatine
  phosphokinase increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Blood
  potassium decreased</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Low density
  lipoprotein increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Neutrophil
  count increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PSA increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Weight
  decreased</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White blood
  cell count increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 rowspan=7 valign=top style='width:150.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Injury, poisoning and procedural complications</span></p>
  </td>
  <td width=131 valign=top style='width:98.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Perineal
  injury<sup>15</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=131 rowspan=6 valign=top style='width:98.3pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Surgical
  procedure repeated</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contusion</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Post-procedural
  urine leak</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Procedural
  pain</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Post-procedural
  discharge</span></p>
  </td>
 </tr>
 <tr>
  <td width=264 valign=top style='width:2.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fall</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The following terms represent a group of related events that
describes a medical condition rather than a single event.</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>1  </span></sup><span
lang=EN-GB>Genito-urinary tract infection (urinary tract infection, orchitis,
epididymitis, cystitis).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>2  </span></sup><span
lang=EN-GB>Anorectal discomfort (proctalgia, rectal tenesmus).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>3  </span></sup><span
lang=EN-GB>Rectal haemorrhage (anal haemorrhage).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>4  </span></sup><span
lang=EN-GB>Hepatotoxicity (alanine aminotransferase increased, aspartate
aminotransferase increased).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>5  </span></sup><span
lang=EN-GB>Back pain (intervertebral disc protrusion).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>6  </span></sup><span
lang=EN-GB>Dysuria (bladder pain, bladder spasm, hypertonic bladder, urethral
spasm, urinary tract pain).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>7  </span></sup><span
lang=EN-GB>Micturition disorders (micturition urgency, pollakiuria, nocturia,
urine flow decreased, urinary straining).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>8  </span></sup><span
lang=EN-GB>Urinary incontinence (urge incontinence, incontinence, stress
urinary incontinence).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>9  </span></sup><span
lang=EN-GB>Perineal pain (pelvic pain).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>10  </span></sup><span
lang=EN-GB>Male sexual dysfunction (erectile dysfunction, ejaculation failure,
dyspareunia, ejaculation disorder, hypospermia, painful ejaculation, retrograde
ejaculation, sexual dysfunction, semen volume decreased).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>11 </span></sup><span
lang=EN-GB>Genital pain (penile pain, testicular pain, scrotal pain,
non-infective orchitis, spermatic cord inflammation, genital contusion).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>12 </span></sup><span
lang=EN-GB>Prostatic pain (prostatism, prostatic disorders, prostatic
fibrosis).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>13 </span></sup><span
lang=EN-GB>Penile swelling (balanoposthitis).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>14 </span></sup><span
lang=EN-GB>Abnormal clotting (fibrin D dimer increased, aPTT prolonged, INR
increased).</span></p>

<p class=MsoNormal style='margin-left:7.1pt;text-indent:-7.1pt;line-height:
normal;text-autospace:none'><sup><span lang=EN-GB>15 </span></sup><span
lang=EN-GB>Perineal injury (post-procedural haematoma, necrosis, perineal
haematoma, pelvic haematoma).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Erectile dysfunction</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>In the Phase III
European study, 60 (30.5&nbsp;%) of patients in the TOOKAD-VTP arm experienced
erectile dysfunction and 16 (8.1&nbsp;%) experienced ejaculation failure. 53 (26.9&nbsp;%)
patients experienced erectile dysfunction for more than 6 months, including <span
lang=EN-GB>34 (17.3&nbsp;%) patients in whom the erectile dysfunction had not
resolved at the end of the study</span>. When the analysis was restricted to
patients that underwent unilateral VTP, 33 (16.8&nbsp;%) patients experienced
erectile dysfunction for more than 6 months, including<span lang=EN-GB> 17 (8.6&nbsp;%)
patients in whom the erectile dysfunction had not resolved at the end of the
study</span>.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Urinary retention</span></i></p>

<p class=MsoNormal style='line-height:normal'>In the Phase III European study,
30 (15.2&nbsp;%) patients experienced urinary retention. The median time to
onset of urinary retention was 3 days (1&#8209;417). The median duration was 10
days (1&#8209;344).</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Genito-urinary infections</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The most common
infections are orchitis, epididymitis and urinary tract infections including
cystitis. </span>In the Phase III European study, 20 (10.2&nbsp;%) patients in
the TOOKAD-VTP arm experienced genito&#8209;urinary infection. In 5 (2.5&nbsp;%)
patients, the infection was considered serious. The median time to onset of genito&#8209;urinary
infections was 22.5 days (4&#8209;360). The median duration was 21 days (4&#8209;197).</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Urinary incontinence</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>In the Phase III
European study, 25 (12.7&nbsp;%) patients experienced urinary incontinence
(including incontinence, stress urinary incontinence and urge incontinence).
The median time to onset of urinary incontinence was 4 days (1&#8209;142). In
18 patients the adverse event resolved with a median duration of 63.5 days (1&#8209;360),
and the adverse event was still ongoing at the end of the study for 7 patients.
Only 1&nbsp;(0.5&nbsp;%) patient had a severe (Grade&nbsp;3) urinary
incontinence. None of these patients required an operation for incontinence.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Perineal injury, perineal pain and prostatitis</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Perineal injury and perineal pain occurred in 46 (23.4&nbsp;%) patients
in the controlled Phase</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>III
European study.</span><span lang=EN-GB> </span><span lang=EN-GB>In some cases pain
relief was required for perineal pain or anorectal discomfort. One patient had
Grade</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>3 perineal pain that
started 35</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>weeks after the
VTP</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>procedure, and lasted
for about 35</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>weeks before
resolving without sequelae.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Prostatitis occurred in 7 (3.6 %) patients</span><span lang=EN-GB> </span><span
lang=EN-GB>in the controlled Phase III European study. One patient had Grade</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>3 prostatitis considered as serious that
started 4</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>days after the
VTP</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>procedure, and lasted
for 31&nbsp;days before resolving without sequelae.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Urethral stenosis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the pivotal
Phase III European study, moderate or severe urethral stenosis developed in 2 (1.0&nbsp;%)
patients 5&nbsp;to&nbsp;6&nbsp;months post&#8209;procedure. This required
urethral dilatation (see section</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Additional adverse reactions in the Phase II prostate cancer studies
and Special Authorization</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Extraprostatic necrosis</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Two cases of excessive extraprostatic necrosis occurred due to
incorrect laser calibration without clinical sequelae. One case of external
urethral fistula occurred due to fibre misplacement (see section</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Phototoxicity</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In a patient treated at 2&nbsp;mg/kg of TOOKAD, one case of
Grade&nbsp;3 ischaemic optic neuropathy was reported 33&nbsp;days after the
VTP&nbsp;procedure. This resolved with a small defect in the visual field.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Prostatic abscess</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One serious
adverse event of prostatic abscess which was considered severe was reported in
the study performed in Latin America in a patient who had a unilateral VTP
procedure. The case resolved within three days.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Rep<span
style='letter-spacing:.05pt'>o</span>rti<span style='letter-spacing:.05pt'>n</span>g<span
style='letter-spacing:-.4pt'> </span>of<span style='letter-spacing:-.1pt'> </span>suspect<span
style='letter-spacing:-.05pt'>e</span>d<span style='letter-spacing:-.4pt'> </span>ad<span
style='letter-spacing:.05pt'>v</span>erse<span style='letter-spacing:-.4pt'> </span>r<span
style='letter-spacing:.05pt'>e</span>actio<span style='letter-spacing:.05pt'>n</span>s</span></u></p>

<p class=MsoNormal style='margin-right:21.65pt;line-height:normal'><span
lang=EN-GB>Rep<span style='letter-spacing:.05pt'>o</span>rti<span
style='letter-spacing:.05pt'>n</span>g<span style='letter-spacing:-.4pt'> </span>su<span
style='letter-spacing:-.05pt'>s</span>pected<span style='letter-spacing:-.45pt'>
</span>ad<span style='letter-spacing:.05pt'>v</span>erse<span style='letter-spacing:
-.35pt'> </span>rea<span style='letter-spacing:-.05pt'>c</span>ti<span
style='letter-spacing:.05pt'>o</span>ns<span style='letter-spacing:-.4pt'> </span>a<span
style='letter-spacing:.05pt'>f</span>ter<span style='letter-spacing:-.2pt'> </span>auth<span
style='letter-spacing:.05pt'>o</span>risation<span style='letter-spacing:-.3pt'>
</span>of<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:
-.05pt'>t</span>he<span style='letter-spacing:-.15pt'> </span><span
style='letter-spacing:-.05pt'>m</span>e<span style='letter-spacing:.05pt'>d</span>icinal<span
style='letter-spacing:-.45pt'> </span>pro<span style='letter-spacing:.05pt'>d</span>uct<span
style='letter-spacing:-.4pt'> </span>is<span style='letter-spacing:-.05pt'> </span>i<span
style='letter-spacing:-.1pt'>m</span>p<span style='letter-spacing:.05pt'>o</span>rtant.<span
style='letter-spacing:-.45pt'> </span>It allows<span style='letter-spacing:
-.3pt'> </span>c<span style='letter-spacing:.05pt'>o</span>ntinued<span
style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.05pt'>m</span>o<span
style='letter-spacing:.05pt'>n</span>it<span style='letter-spacing:.05pt'>o</span>ri<span
style='letter-spacing:.05pt'>n</span>g<span style='letter-spacing:-.45pt'> </span>of<span
style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>t</span>he<span
style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>b</span>e<span
style='letter-spacing:-.05pt'>n</span>efit/risk<span style='letter-spacing:
-.45pt'> </span><span style='letter-spacing:.05pt'>b</span>alance<span
style='letter-spacing:-.35pt'> </span>of<span style='letter-spacing:-.05pt'> </span>the<span
style='letter-spacing:-.1pt'> m</span>e<span style='letter-spacing:.05pt'>d</span>icinal<span
style='letter-spacing:-.45pt'> </span>pro<span style='letter-spacing:.05pt'>d</span>uc<span
style='letter-spacing:-.05pt'>t</span>.<span style='letter-spacing:-.35pt'> </span>Healthcare
profes<span style='letter-spacing:-.05pt'>s</span>ionals<span style='letter-spacing:
-.6pt'> </span>are<span style='letter-spacing:-.15pt'> </span>asked<span
style='letter-spacing:-.25pt'> </span>to<span style='letter-spacing:-.05pt'> </span>report<span
style='letter-spacing:-.25pt'> </span>any<span style='letter-spacing:-.1pt'> </span>su<span
style='letter-spacing:-.05pt'>s</span>pected<span style='letter-spacing:-.45pt'>
</span>ad<span style='letter-spacing:.05pt'>v</span>erse<span style='letter-spacing:
-.35pt'> </span>rea<span style='letter-spacing:-.05pt'>c</span>ti<span
style='letter-spacing:.05pt'>o</span>ns<span style='letter-spacing:-.4pt'> </span>via<span
style='letter-spacing:-.15pt'> </span><span style='background:lightgrey'>the<span
style='letter-spacing:-.15pt'> </span>nati<span style='letter-spacing:.05pt'>o</span>nal<span
style='letter-spacing:-.35pt'> </span>rep<span style='letter-spacing:.05pt'>o</span>rti<span
style='letter-spacing:.05pt'>n</span>g<span style='letter-spacing:-.35pt'> </span><span
style='letter-spacing:-.05pt'>s</span><span style='letter-spacing:.1pt'>y</span><span
style='letter-spacing:-.05pt'>s</span>t<span style='letter-spacing:.05pt'>e</span>m
listed<span style='letter-spacing:-.2pt'> </span>in<span style='letter-spacing:
-.1pt'> </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix<span style='letter-spacing:-.45pt'> </span><span
style='letter-spacing:.05pt'>V</span></span><span style='color:windowtext;
text-decoration:none'>.</span></a></span></p>

<p class=MsoNormal style='margin-right:21.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>There is limited clinical information on overdose involving TOOKAD.
Healthy subjects have been exposed to doses up to 15&nbsp;mg/kg of padeliporfin
di&#8209;potassium (corresponding to 13.73&nbsp;mg/kg of padeliporfin) without
light activation and 23&nbsp;patients have been treated with 6&nbsp;mg/kg of
padeliporfin di&#8209;potassium (corresponding to 5.49&nbsp;mg/kg of
padeliporfin) without significant safety issues. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>However, a prolongation of photosensitisation is possible and
precautions against light exposure should be maintained for an additional 24&nbsp;hours
(see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>An overdose of the laser light may increase the risk of undesirable
extraprostatic necrosis (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Pharmacotherapeutic group: Sensitizers used in photodynamic/radiation
therapy, ATC code: L01XD07</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Padeliporfin is retained within the vascular system. When activated
with 753&nbsp;nm wavelength laser light, padeliporfin triggers a cascade of
pathophysiological events resulting in focal necrosis within a few days. Activation
within the illuminated tumour vasculature, generates oxygen radicals (•OH, O</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
position:relative;top:2.5pt'><img width=8 height=17
src="Tookad%204182%20-%20En%20Annexes%20(clean)%20-%20FINAL_files/image002.png"></span><span
lang=EN-GB> )<span style='color:black'> </span>causing local hypoxia that induces
the release of nitric oxide <span style='color:black'>(•NO) </span>radicals.
This results in transient arterial vasodilatation that triggers the release of
the vasoconstrictor, endothelin&#8209;1. Rapid consumption of the <span
style='color:black'>•NO </span>radicals, by oxygen radicals, leads to the
formation of reactive nitrogen species (RNS) (e.g. peroxynitrite), in parallel
to arterial constriction. In addition, impaired deformability is thought to
enhance erythrocyte aggregability and formation of blood clots at the interface
of the arterial supply (feeding arteries) and tumour microcirculation, results
in occlusion of the tumour vasculature. This is enhanced by RNS&#8209;induced
endothelial cell apoptosis and initiation of self-propagated tumour cells
necrosis through peroxidation of their membrane.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In patients with localised prostate cancer who received TOOKAD&#8209;VTP,
necrosis was observed by Magnetic Resonance Imaging (MRI) at day&nbsp;7. There
was a correlation between the total energy delivered and the volume of necrosis
observed at day&nbsp;7. The LDI corresponds to the ratio of the cumulative
length of illuminated fibre tips (cm) to the volume (cc) of the targeted zone to
be treated. The targeted zone corresponds to the lobe containing the positive
biopsies. Its volume is measured after prostate delineation using the treatment
guidance software. In Phase&nbsp;II studies, treatment conditions corresponding
to an LDI&nbsp;&#8805;&nbsp;1 were associated with a mean rate of necrosis of
the targeted zone at day&nbsp;7 of 89&nbsp;% ±&nbsp;20.75 for unilateral
treatment. An LDI&nbsp;&#8805;&nbsp;1 appeared to be associated with a greater
volume of necrosis on Day&nbsp;7&nbsp;MRI and greater share of patients with
negative biopsy at 6&nbsp;months compared with an LDI&nbsp;&lt;&nbsp;1 (see section
4.2).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There was no significant correlation between the percentage of
prostate necrosis on Day&nbsp;7&nbsp;MRI and the likelihood of a negative
prostate biopsy at follow-up.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>Phase III Study (PCM301)</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The pivotal open-label Phase&nbsp;III study (PCM301), conducted in
10 European countries, randomised 413 patients to TOOKAD-VTP arm or AS arm.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The main inclusion criteria were low&#8209;risk prostate cancer with
Gleason 3&nbsp;+&nbsp;3 prostate adenocarcinoma as a maximum, two to three cores
positive for cancer and a maximum cancer core length of 5&nbsp;mm in any core
(at least 3&nbsp;mm for patients with only one positive core), clinical stage
up to T2a, PSA&nbsp;&#8804;&nbsp;10&nbsp;ng/mL, prostate volume equal or
greater than 25&nbsp;cc and less than 70&nbsp;cc.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The main exclusion criteria were any prior or current treatment for
prostate cancer, any surgical intervention for benign prostatic hypertrophy,
life expectancy less than 10 years, medical conditions which preclude the use
of general anaesthesia.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The VTP procedure consisted of a 10 minutes IV injection of 4&nbsp;mg/kg
of TOOKAD followed by 22&nbsp;minutes 15&nbsp;seconds of illumination with
753&nbsp;nm laser light at 200 J/cm of fibre delivered using interstitial
optical fibres, inserted transperineally into the prostate gland. In case of
unilateral disease, focal treatment of one lobe was to be applied. In case of
bilateral disease (discovered at entry or during follow-up), bilateral
treatment was to be applied, either simultaneously or consecutively.
Retreatment of lobes found positive for cancer at 12&#8209;months follow-up was
allowed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>AS involved serial absolute PSA measurements and ultrasound&#8209;guided
prostatic biospy at 12 and 24&nbsp;months.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The study had two co&#8209;primary endpoints for TOOKAD&#8209;VTP in
comparison to AS:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-        A: The rate of absence of definite cancer based on
histology at 24&nbsp;months, </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-        B: The difference in rate of treatment failure associated
with observed progression of disease from low to moderate or higher risk
prostate cancer. Moderate/higher risk prostate cancer was defined as any of the
following: &gt;&nbsp;3&nbsp;cores definitively positive for cancer; Gleason
primary or secondary pattern &#8805;&nbsp;4; at least 1&nbsp;cancer core length&nbsp;&gt;&nbsp;5&nbsp;mm;
PSA&nbsp;&gt;&nbsp;10&nbsp;ng/mL in 3 consecutive measures; T3 prostate cancer;
metastasis; prostate cancer&#8209;related death.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='letter-spacing:.05pt'>A</span><span lang=EN-GB>ll<span
style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>p</span>atients<span
style='letter-spacing:-.35pt'> </span><span style='letter-spacing:.05pt'>h</span>ad<span
style='letter-spacing:-.15pt'> </span>Gleason<span style='letter-spacing:-.3pt'>&nbsp;score&nbsp;&#8804;&nbsp;</span><span
style='letter-spacing:.05pt'>3&nbsp;</span>+&nbsp;3<span style='letter-spacing:
-.15pt'> </span>at baseline.<span style='letter-spacing:-.05pt'> </span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='letter-spacing:-.05pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In each table are
also presented the results of patients meeting the indication criteria (</span><span
lang=EN-GB>patients with unilateral low&#8209;risk</span><span lang=EN-GB>
localised prostate cancer excluded the very low-risk)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Table&nbsp;2 gives baseline characteristics by arm.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Table 2: PCM301 – Baseline characteristics by arm for the Intention-To-Treat
(ITT) population and patients meeting the indication criteria</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=179 rowspan=2 valign=top style='width:134.45pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Characteristic</span></b></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=208 colspan=2 style='width:155.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>ITT population</span></b></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:162.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Patients meeting indication criteria</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>TOOKAD&#8209;<br>
  VTP arm</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>N = 206</span></b></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>AS arm</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>N = 207</span></b></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>TOOKAD&#8209;</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>VTP arm</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>N = 80</span></b></p>
  </td>
  <td width=113 style='width:84.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>AS arm</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>N = 78</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=5 style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Age (years)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Mean (SD)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>64.2 (6.70)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>62.9 (6.68)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>63.9 (6.27)</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>62.3 (6.32)</span></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Range: min, max</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>45, 85</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>44, 79</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>48, 74</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>46, 73</span></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Patients aged&nbsp;&gt;&nbsp;75&nbsp;year old, n (%)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>6 (2.9)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>6 (2.9)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Unilateral disease, n (%)</span></b></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>157 (76.2)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>163 (78.7)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>80 (100)</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>78 (100)</span></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Bilateral disease, n (%)</span></b></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>49 (23.8)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>44 (21.3)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>Not applicable</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>Not applicable</span></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=5 style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Clinical stages</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>T1, n (%)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>178 (86.4)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>180 (87.0)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>66 (82.5) </span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>71 (91.0)      </span></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>T2a, n (%)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>28 (13.6)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>27 (13.0)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>14 (17.5)        </span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>7 (9.0)       </span></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=5 style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Total number of positive cores</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Mean (SD)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.1 (0.68)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.0 (0.72)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.2 (0.74)</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.1 (0.76)</span></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Range: min, max</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>1, 3</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>1, 3</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>1, 3</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>1, 3</span></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=5 style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Estimated prostate volume (cc)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Mean (SD)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>42.5 (12.49)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>42.5 (11.76)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>37.2 (9.67)</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>37.6 (9.63)</span></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Range: min, max</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>25, 70</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>25, 70</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>25, 68</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>25, 66</span></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=5 style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>PSA (ng/mL)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Mean (SD)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>6.19 (2.114)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>5.91 (2.049)</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>6.98 (1.796)</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>7.12 (1.704)</span></p>
  </td>
 </tr>
 <tr>
  <td width=179 style='width:134.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Range: min, max</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.1, 10.0</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.5, 10.0</span></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>1.0, 10.0</span></p>
  </td>
  <td width=113 valign=top style='width:84.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>3.1, 10.0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Of the 206&nbsp;subjects randomised TOOKAD&#8209;VTP, 10 did not
receive treatment for various reasons including study withdrawal, meeting
exclusion criteria, non-compliance and other medical events.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Table 3 describes the co-primary efficacy endpoints in the whole
prostate gland and in the treated lobe (ITT population</span><span lang=EN-GB> </span><span
lang=EN-GB>and patients meeting the indication criteria).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Table 3: PCM301 – Co-primary efficacy endpoints – Whole prostate
gland and treated lobe(s)* – ITT population</span></b><span lang=EN-GB> </span><b><span
lang=EN-GB>and patients meeting the indication criteria</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=181 rowspan=2 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-bottom:double windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Number of subjects with</span></b></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=168 colspan=2 style='width:125.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>ITT population</span></b></p>
  </td>
  <td width=271 colspan=2 style='width:203.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Patients meeting indication criteria</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:double windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:0in;margin-left:-5.4pt;margin-bottom:.0001pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>TOOKAD-VTP arm</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>N = 206</span></b></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:double windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>AS arm</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>N = 207</span></b></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:double windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:0in;margin-left:-5.4pt;margin-bottom:.0001pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>TOOKAD-VTP arm</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>N = 80</span></b></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:double windowtext 1.5pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>AS arm</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>N = 78</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:464.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:double windowtext 1.5pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>A: R</span></b><b><span lang=EN-GB>ate of absence of definite
  cancer based on histology at 24&nbsp;months</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Negative biopsy, n (%)</span></b></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>101 (49.0)<sup>a</sup></span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>28 (13.5)<sup>a</sup></span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>36 (45.0)<sup>e</sup>           </span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>8 (10.3)<sup>e</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Negative biopsy in the treated lobe*, n (%)</span></b></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>129 (62.6)<sup>b</sup></span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>40 (19.3)<sup>b</sup></span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>52 (65.0)<sup>f</sup>           </span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>11 (14.1)<sup>f</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>No biopsy result, n (%)</span></b></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>38 (18.4)</span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>86 (41.5)</span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>11 (13.8)          </span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>34 (43.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Subjects who had radical therapy leading to missing biopsy, n (%)</span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>12 (5.8)</span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>  55 (26.6)<sup>c</sup></span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>6 (7.5)</span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>27 (34.6)</span></p>
  </td>
 </tr>
 <tr style='height:16.35pt'>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.35pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
  0in;margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>Other reasons<sup>d</sup>, n (%)</span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'> 26 (12.6)</span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'> 31 (15.0)</span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>5 (6.3)</span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>7 (9.0)</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Positive biopsy, n (%)</span></b></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>67 (32.5)</span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>93 (44.9)</span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>33 (41.3)          </span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>36 (46.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Positive biopsy in the treated lobe*, n (%)</span></b></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='position:relative;top:.5pt'>  </span><span lang=EN-GB
  style='position:relative;top:.5pt'>39(18.9)</span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='position:relative;top:.5pt'>  </span><span lang=EN-GB
  style='position:relative;top:.5pt'>81(39.1)</span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>  17(21.3)</span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>              
  33(42.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 valign=top style='width:464.35pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:double windowtext 1.5pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><sup><span
  lang=EN-GB>a</span></sup><span lang=EN-GB>Risk Ratio (95% CI)  = 3.62 (2.50 ;
  5.26) ; p value &lt; 0.001</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><sup><span
  lang=EN-GB>b</span></sup><span lang=EN-GB>Risk Ratio (95% CI) = 3.24 (2.41 ;
  4.36) ; p value &lt; 0.001</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><sup><span
  lang=EN-GB>c</span></sup><span lang=EN-GB>Among the 60 patients who had
  radical therapy, 5 patients had a Month 24 biopsy</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><sup><span
  lang=EN-GB>d</span></sup><span lang=EN-GB>For example: study withdrawal,
  medical reason, subject refusal</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><sup><span
  lang=EN-GB>e</span></sup><span lang=EN-GB>Risk Ratio (95% CI) = 4.39 (2.18 ;
  8.83) ; p value &lt; 0.001</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><sup><span
  lang=EN-GB>f</span></sup><span lang=EN-GB>Risk Ratio (95% CI) = 4.61 (2.60 ;
  8.16) ; p value &lt; 0.001</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=5 style='width:464.35pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:double windowtext 1.5pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>B:
  Difference in rate of treatment failure associated with observed progression
  of disease</span></b><span lang=EN-GB> </span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Number of subjects progressed at Month 24, n (%)</span></b></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'> 58 (28.2)<sup>g</sup></span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>121 (58.5)<sup>g</sup></span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>27 (33.8)<sup>h</sup>         </span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>53 (67.9)</span><sup><span lang=EN-GB style='position:relative;
  top:.5pt'>h</span></sup><span lang=EN-GB>      </span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Progression to Gleason &#8805; 4</span><span lang=EN-GB
  style='font-size:10.0pt;font-family:"Arial",sans-serif'> </span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>49 (23.8)</span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'> 91 (44.0)</span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>19 (23.8)          </span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>40 (51.3)       </span></p>
  </td>
 </tr>
 <tr>
  <td width=181 valign=top style='width:135.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
  lang=EN-GB>Number of subjects progressed in the treated lobe* at Month 24, n
  (%)</span></b></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>24(11.7)<sup>i</sup></span></p>
  </td>
  <td width=82 valign=top style='width:61.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='position:relative;top:.5pt'>90(43.5)<sup>i</sup></span></p>
  </td>
  <td width=86 valign=top style='width:64.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>7(8.8)<sup>j</sup></span></p>
  </td>
  <td width=185 valign=top style='width:138.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>39(50.0)<sup>j</sup></span></p>
  </td>
 </tr>
 <tr style='height:27.45pt'>
  <td width=619 colspan=5 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:27.45pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><sup>g</sup>Adjusted
  Hazard Ratio (95% CI) = 0.34 (0.24&nbsp;; 0.46) ; p value &#8804; 0.001</p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><sup>h</sup>Adjusted
  Hazard Ratio (95% CI) = 0.31 (0.20&nbsp;; 0.50)&nbsp;; p value &#8804; 0.001</p>
  <p class=MsoBodyText style='margin-left:1.7pt;text-indent:-1.7pt'><sup><span
  lang=EN-GB style='color:windowtext;position:relative;top:.5pt;font-style:
  normal'>i</span></sup><span lang=EN-IE style='color:windowtext;font-style:
  normal'>Adjusted Hazard Ratio (95% CI) = 0.17 (0.12 ; 0.27) ; p value &#8804;
  0.001</span></p>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><sup>j</sup>Adjusted
  Hazard Ratio (95% CI) = 0.11 (0.05 ; 0.25) ; p value &#8804; 0.001</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>* The treated</span><span
lang=EN-GB> lobe</span><span lang=EN-GB>(s) in the AS arm was defined as the </span><span
lang=EN-GB>lobe</span><span lang=EN-GB>(s)</span><span lang=EN-GB> with disease
at baseline</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A secondary objective
was to determine the difference between the two arms with regard to the rate of
subsequent radical therapy for prostate cancer. Of 58&nbsp;patients that
progressed in the TOOKAD&#8209;VTP arm, only 11 underwent radical therapy, 18
patients underwent a second VTP&nbsp;procedure and 29 had not received further treatment
at the end of the study. Of 121&nbsp;patients that progressed in the AS arm, 54
underwent radical therapy and 67 had not received any active treatment at the
end of the study. Patients in the AS arm were not offered subsequent VTP. In
assessing overall tolerability by Month&nbsp;24, post enrolment patients who
underwent a radical therapy were also counted in the scoring of prostate symptoms
and erectile function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table 4: PCM301 – Number of subjects with radical treatment at 24
months – ITT population and patients meeting the indication criteria</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='margin-left:-5.65pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=196 rowspan=2 valign=top style='width:147.15pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Characteristic</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=208 colspan=2 style='width:155.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='color:windowtext;font-style:normal'>ITT population</span></b></p>
  </td>
  <td width=207 colspan=2 style='width:155.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='color:windowtext;font-style:normal'>Patients meeting
  indication criteria</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:0in;margin-left:-5.4pt;margin-bottom:.0001pt;text-align:center'><b><span
  lang=EN-GB style='color:windowtext;font-style:normal'>TOOKAD-VTP arm</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>N = 206</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='color:windowtext;font-style:normal'>AS arm</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>N = 207</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText align=center style='margin-top:0in;margin-right:-5.4pt;
  margin-bottom:0in;margin-left:-5.4pt;margin-bottom:.0001pt;text-align:center'><b><span
  lang=EN-GB style='color:windowtext;font-style:normal'>TOOKAD-VTP arm</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='color:windowtext;font-style:normal'>N = 80</span></b></p>
  </td>
  <td width=104 valign=top style='width:77.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='color:windowtext;font-style:normal'>AS arm</span></b></p>
  <p class=MsoBodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='color:windowtext;font-style:normal'>N = 78</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=196 valign=top style='width:147.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Number of
  subjects who initiated a radical treatment, n&nbsp;(%)</span></b></p>
  </td>
  <td width=104 style='width:78.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>12 (5.8)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>62 (29.9)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>6 (7.5)</span></p>
  </td>
  <td width=104 style='width:77.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>28 (35.9)</span></p>
  </td>
 </tr>
 <tr>
  <td width=196 valign=top style='width:147.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Number of
  subjects who initiated a radical treatment after progression, n (%)</span></b></p>
  </td>
  <td width=104 style='width:78.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>11 (5.3)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>54 (26.1)</span></p>
  </td>
  <td width=104 style='width:77.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>5 (6.3)</span></p>
  </td>
  <td width=104 style='width:77.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>25 (32.1)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>Effect on urinary morbidity (IPSS) and erectile function (IIEF)
following TOOKAD&#8209;VTP</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>As shown in Table 5, in PCM301 study, the International Prostate
Symptoms Score (IPSS) showed, a moderate increase 7&nbsp;days after the VTP&nbsp;procedure,
in both the ITT population and in patients meeting the indication criteria.
Those results were improved at Month&nbsp;3 and back to baseline values at
Month&nbsp;6, with further improvement until Month 24. In the Active
Surveillance arm, the IPSS score slightly worsened over time until Month 24.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Table 5: PCM301 – Effect on urinary morbidity (IPSS) </span></b><b><span
lang=EN-GB>– ITT population and patients meeting the indication criteria</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=611
 style='margin-left:-5.15pt;border-collapse:collapse;border:none'>
 <tr style='height:28.25pt'>
  <td width=82 valign=top style='width:61.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=264 colspan=4 style='width:198.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>ITT population</span></b></p>
  </td>
  <td width=264 colspan=4 style='width:198.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Patients meeting indication criteria</span></b></p>
  </td>
 </tr>
 <tr style='height:28.25pt'>
  <td width=82 rowspan=2 valign=top style='width:61.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=132 colspan=2 style='width:99.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>TOOKAD-VTP arm</span></b></p>
  </td>
  <td width=132 colspan=2 style='width:99.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>AS arm</span></b></p>
  </td>
  <td width=132 colspan=2 style='width:99.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>TOOKAD-VTP arm</span></b></p>
  </td>
  <td width=132 colspan=2 style='width:99.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>AS arm</span></b></p>
  </td>
 </tr>
 <tr style='height:27.95pt'>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>n</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Mean score (SD)</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>n</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Mean score (SD)</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>n</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Mean score (SD) </span></b></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>n</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Mean score (SD)</span></b></p>
  </td>
 </tr>
 <tr style='height:12.5pt'>
  <td width=82 valign=top style='width:61.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Baseline</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>179</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.6 (6.09)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>185</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.6 (5.30)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>71</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.7 (5.69)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>73</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.0 (4.34)</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=82 valign=top style='width:61.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Day 7</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>180</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>14.8 (8.64)</span></p>
  </td>
  <td width=132 colspan=2 valign=top style='width:99.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>Not applicable</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>72</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>14.2 (8.89)</span></p>
  </td>
  <td width=132 colspan=2 valign=top style='width:99.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>Not applicable</span></p>
  </td>
 </tr>
 <tr style='height:12.5pt'>
  <td width=82 valign=top style='width:61.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Month 3</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>179</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>9.6 (6.86)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>190</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.2 (5.75)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>71</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8.7 (5.72)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>72</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.6 (5.11)</span></p>
  </td>
 </tr>
 <tr style='height:12.5pt'>
  <td width=82 valign=top style='width:61.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Month 6</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>182</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.5 (6.06)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>189</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.8 (5.84)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>74</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.4 (5.33)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>73</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.3 (5.36)</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=82 valign=top style='width:61.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Month 12</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>177</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.2 (5.85)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>173</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.3 (5.95)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>71</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>5.7 (5.01)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>68</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>7.1 (5.75)</span></p>
  </td>
 </tr>
 <tr style='height:12.5pt'>
  <td width=82 valign=top style='width:61.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Month 24*</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>165</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>6.6 (5.47)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>154</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8.2 (6.47)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>66</span></p>
  </td>
  <td width=94 valign=top style='width:70.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>5.5 (5.34)</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>55</span></p>
  </td>
  <td width=94 valign=top style='width:70.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>8.6 (6.56)</span></p>
  </td>
 </tr>
</table>

<p class=CorpsdeTexte align=left style='margin:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>*Scores at Month 24 include patients who
underwent radical therapy</span></p>

<p class=CorpsdeTexte align=left style='margin:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=CorpsdeTexte align=left style='margin:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>As shown in Table 6, in the VTP arm of PCM301
study, erectile function domain scores of the 15&#8209;question International
Index of Erectile Function (IIEF&#8209;15) questionnaire showed a marked
decrease, 7 days after the VTP procedure followed by a subsequent improvement
in the following months up to Month 24, in the ITT population and in patients
meeting the indication criteria. </span></p>

<p class=CorpsdeTexte align=left style='margin:0in;text-align:left'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table 6: PCM301 – Effect on erectile function (IIEF) </span></b><b><span
lang=EN-GB>– ITT population and patients meeting the indication criteria</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=612
 style='margin-left:-5.15pt;border-collapse:collapse;border:none'>
 <tr style='height:28.25pt'>
  <td width=82 valign=top style='width:61.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=265 colspan=4 style='width:198.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>ITT population</span></b></p>
  </td>
  <td width=265 colspan=4 style='width:198.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Patients meeting indication criteria</span></b></p>
  </td>
 </tr>
 <tr style='height:28.25pt'>
  <td width=82 rowspan=2 valign=top style='width:61.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=132 colspan=2 style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>TOOKAD-VTP arm</span></b></p>
  </td>
  <td width=132 colspan=2 style='width:99.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>AS arm</span></b></p>
  </td>
  <td width=132 colspan=2 style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>TOOKAD-VTP arm</span></b></p>
  </td>
  <td width=132 colspan=2 style='width:99.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>AS arm</span></b></p>
  </td>
 </tr>
 <tr style='height:27.95pt'>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>n</span></b></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Mean score (SD)</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>n</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Mean score (SD)</span></b></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>n</span></b></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Mean score (SD) </span></b></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>n</span></b></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.95pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><b><span lang=EN-GB>Mean score (SD)</span></b></p>
  </td>
 </tr>
 <tr style='height:12.5pt'>
  <td width=82 valign=top style='width:61.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Baseline</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>184</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>18.6 (10.22) </span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>188</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>20.6 (9.92)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>74</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>18.4 (10.31)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>74</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>20.8 (10.02)</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=82 valign=top style='width:61.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Day 7</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>165</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>11.5 (10.96)</span></p>
  </td>
  <td width=132 colspan=2 valign=top style='width:99.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>Not applicable</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>68</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>10.1 (10.82)</span></p>
  </td>
  <td width=132 colspan=2 valign=top style='width:99.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>Not applicable</span></p>
  </td>
 </tr>
 <tr style='height:12.5pt'>
  <td width=82 valign=top style='width:61.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Month 3</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>171</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>14.7 (10.48)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>182</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>21.0 (9.84)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>69</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>14.3 (10.81)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>70</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>21.7 (9.95)</span></p>
  </td>
 </tr>
 <tr style='height:12.5pt'>
  <td width=82 valign=top style='width:61.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Month 6</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>176</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>16.1 (9.98)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>185</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>20.4 (9.83) </span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>68</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>16.9 (9.78)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>72</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>20.6 (9.85)</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=82 valign=top style='width:61.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Month 12</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>170</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>15.1 (10.28) </span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>167</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>19.9 (10.29)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>70</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>16.7 (10.18)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>65</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>20.4 (10.44)</span></p>
  </td>
 </tr>
 <tr style='height:12.5pt'>
  <td width=82 valign=top style='width:61.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
  lang=EN-GB>Month 24*</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>159</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>15.0 (10.70) </span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>152</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>16.8 (11.17)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>62</span></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>15.4 (11.11)</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>54</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.5pt'>
  <p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
  line-height:normal'><span lang=EN-GB>16.4 (11.10)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>*Scores at Month 24 include patients who underwent radical therapy</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The pharmacokinetic properties of TOOKAD were studied in
42&nbsp;healthy human male subjects (without photoactivation) and in
70&nbsp;patients with localised prostate cancer (after photoactivation).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In healthy human male subjects, the mean volume of distribution
ranged from 0.064-0.279&nbsp;L/kg, for posologies from
1.25&nbsp;to&nbsp;15&nbsp;mg/kg of padeliporfin di&#8209;potassium indicating
distribution into extracellular fluid. A similar mean distribution volume was
seen in patients with localised prostate cancer treated with
2&nbsp;and&nbsp;4&nbsp;mg/kg of padeliporfin di&#8209;potassium (0.09&#8209;0.10&nbsp;L/kg
respectively). </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Padeliporfin di&#8209;potassium is highly bound to human plasma
proteins (99&nbsp;%).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>In vitro</span></i><span lang=EN-GB> studies indicate that TOOKAD is
unlikely to be a substrate of OATP1B1, OATP1B3, OCT1, OATP2B1, P-gp, BCRP, MRP2
or BSEP hepatic uptake transporters.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Minimal metabolism of padeliporfin was observed in <i>in vitro</i>
metabolism studies in human liver microsomes and S9 fractions. No metabolites
of padeliporfin were observed in these studies.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>No <i>in vitro</i> or <i>in vivo</i> studies have been conducted
with radiolabelled padeliporfin. Therefore, the possibility for some <i>in vivo</i>
metabolism of padeliporfin cannot be fully excluded.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>In vitro</span></i><span lang=EN-GB> studies indicate that TOOKAD is
unlikely to be an inhibitor of CYP450 enzymes.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>In vitro</span></i><span lang=EN-GB> studies indicate that TOOKAD
does not inhibit </span>P-gp, OAT1, OAT3, OCT2, OCT1, BCRP and BSEP but it <span
lang=EN-GB>could inhibit both OATP1B1 and OATP1B3 transporters (see section
4.5).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Clearance of padeliporfin di&#8209;potassium in healthy male
subjects treated from 1.25&nbsp;mg/kg up to</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>15&nbsp;mg/kg of padeliporfin di&#8209;potassium ranged from
0.0245&nbsp;to&nbsp;0.088&nbsp;L/h/kg. Based on popPK analysis the estimated
half-life is 1.19&nbsp;h&nbsp;±&nbsp;0.08 at 4&nbsp;mg/kg of padeliporfin di&#8209;potassium.
A similar mean clearance range was seen in patients with localised prostate
cancer treated with 4&nbsp;mg/kg and 2&nbsp;mg/kg of padeliporfin di&#8209;potassium
(0.04&#8209;0.06&nbsp;L/h/kg respectively). Urinary excretion of padeliporfin
in healthy human subjects was very low (&lt;&nbsp;0.2&nbsp;% of the dose).
Taking into account its molecular mass and the very low urinary excretion of
the molecule, faecal elimination is the most probable route of elimination in
human.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Elderly population</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Very few patients aged over 75 years were enrolled into studies
where pharmacokinetic measurements were taken so it is not known if there is a
difference in these older patients compared to patients less than&nbsp;75&nbsp;years
of age (see sections 4.2 and 5.1).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Linearity/non-linearity</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In healthy human male subjects, the C<sub>max</sub> was shown to be
linear from 1.25&nbsp;mg/kg to 15&nbsp;mg/kg of padeliporfin di&#8209;potassium,
covering the therapeutic range.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Effects of covariates on pharmacokinetic properties</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The effects of age, weight and race were investigated in healthy
volunteers and patients.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The results of the population PK study showed that age, race, health
status and markers of hepatic function were unlikely to have a substantial and
biologically significant impact on the pharmacokinetics of TOOKAD.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The body weight of patients (range 60&#8209;120&nbsp;kg) presented a
minor impact on the TOOKAD pharmacokinetic parameters for doses up to
5&nbsp;mg/kg of padeliporfin di&#8209;potassium.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non-clinical
data reveal no special hazard for humans based on conventional studies of
safety pharmacology and repeated dose toxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> genotoxicity testing identified padeliporfin as having weak
potential to induce clastogenicity when illuminated by ultraviolet (UV); this correlates
with the mechanism of action (formation of reactive oxygen species).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Padeliporfin was
shown to be cytotoxic in the presence of UVA irradiation (<i>in vitro</i>) and
considered phototoxic in the guinea pig (<i>in vivo</i>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Carcinogenicity
and reproductive toxicity studies have not been conducted with padeliporfin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mannitol (E421)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product must not be mixed with other medicinal products except those mentioned
in section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Unopened vial</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5 years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>After
reconstitution</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The chemical and
physical stability of TOOKAD after reconstitution with 5&nbsp;% glucose
solution, in its vial, has been demonstrated for 8&nbsp;hours at 15°C&#8209;25°C
and at 5°C&nbsp;±&nbsp;3°C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>From a
microbiological point of view, the product should be used immediately. If not
used immediately, in&#8209;use storage times and conditions prior to use are
the responsibility of the user.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator
(2°C&#8209;8°C).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions after reconstitution of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>TOOKAD 183&nbsp;mg
powder for solution for injection</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amber type&nbsp;I
glass vial, sealed with a rubber stopper crimped with an aluminium seal and
covered with a blue plastic flip&#8209;off cap, containing 183&nbsp;mg padeliporfin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size: 1
vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>TOOKAD 366&nbsp;mg
powder for solution for injection</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Amber type&nbsp;I
glass vial, sealed with a rubber stopper crimped with an aluminium seal and
covered with a white plastic flip&#8209;off cap, containing 366&nbsp;mg padeliporfin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size: 1
vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6     Special precautions for
disposal and other handling</span></b></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The preparation
of the solution should take place in a dimmed-light environment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD is
prepared by reconstituting the powder for solution for injection with:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>-        20&nbsp;mL
of 5&nbsp;% glucose solution for TOOKAD 183&nbsp;mg,</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>-        40&nbsp;mL
of 5&nbsp;% glucose solution for TOOKAD 366&nbsp;mg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The vial should
then be swirled gently for 2&nbsp;minutes. Each mL of the resulting solution
will contain 9.15&nbsp;mg of padeliporfin. The vial should rest in an upright
position for 3&nbsp;minutes without further shaking or moving. Due to the
photosensitising properties of TOOKAD, the content of the vial should then be
transferred into an opaque syringe that should be held in an upright position
for 3&nbsp;minutes to ensure any foam disappears. An injection filter of 0.22&nbsp;µm
and an opaque tubing should be used to administer the medicinal product to the
patient. Standard handling of syringes should follow.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The reconstituted
solution is dark. If not used immediately, in&#8209;use storage times and
conditions prior to use are the responsibility of the user.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Steba Biotech
S.A.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>7 Place du Théâtre</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>L-2613 Luxembourg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Luxembourg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1228/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1228/002</span><b><span
lang=EN-GB><br clear=all style='page-break-before:always'>
</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency </span><span lang=EN-GB>http://www.ema.europa.eu.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
line-height:normal'><b><span lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
0in;margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-42.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>A.      MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE </span></b></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
11.0pt;margin-left:42.35pt;text-indent:-42.35pt;page-break-after:avoid;
text-autospace:none'><b><span lang=EN-GB style='color:black'>B.      CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>C.      OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>D.      CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>A.      MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB style='color:black'>Name and address of the
manufacturer responsible for batch release</span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=PT style='color:black'>PRAXIS PHARMACEUTICAL S.A.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=PT style='color:black'>C/ Hermanos Lumiere 5</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=PT style='color:black'>Parque Tecnologico de Alava (Miñano)</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Vitoria-Gasteiz</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Alava 01510</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>Spain</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB style='color:black'>B.      CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section 4.2).</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>C.      OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Periodic
safety update reports </span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>The
requirements for submission of periodic safety update reports for this
medicinal product are set out in the list of Union reference dates (EURD list)
provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent
updates published on the European medicines web-portal.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>The
marketing authorisation holder shall submit the first periodic safety update
report for this product within 6 months following authorisation.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE
AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB
style='color:black'>&nbsp;</span></b></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'>Risk
Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>The MAH shall perform the required
pharmacovigilance activities and interventions detailed in the agreed RMP
presented in Module 1.8.2 of the marketing authorisation and any agreed
subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-right:6.0pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>At
the request of the European Medicines Agency;</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Whenever
the risk management system is modified, especially as the result of new
information being received that may lead to a significant change to the
benefit/risk profile or as the result of an important (pharmacovigilance or
risk minimisation) milestone being reached. </span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'>Additional
risk minimisation measures</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Prior
to launch of TOOKAD in each Member State the marketing authorisation holder
(MAH) must agree about the content and format of the educational programme,
including communication media, distribution modalities, and any other aspects
of the programme, with the National Competent Authority. </span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
educational programme is aimed at increasing awareness and providing
information concerning the signs and symptoms of certain important identified
risks of padeliporfin, including photosensitivity, and also information on the
existing therapeutic approaches (including VTP with TOOKAD) for the treatment
of the type of prostate cancer, potential benefits, risks and uncertainties of
VTP with TOOKAD.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The MAH
shall ensure that in each Member State where TOOKAD is marketed, all healthcare
professionals and patients/carers who are expected to prescribe and use TOOKAD
have access to/are provided with the following educational package:</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Patient
information guide</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Physician
guideline</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
Patient information guide about TOOKAD should contain the following key
elements:</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Information
on the existing therapeutic approaches (including VTP with TOOKAD) for the
treatment of the type of prostate cancer</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Information
on the potential benefits, risks and uncertainties of VTP with TOOKAD,
including: uncertainties on long-lasting benefit of TOOKAD; uncertainties on
long-term safety of TOOKAD and efficacy/safety of any further treatments
required such as radical prostatectomy</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Information
on adverse drug reactions and the likelihood of them getting them, including:
erectile dysfunction, urinary incontinence, urinary retention/urethral
stricture, and photosensitivity and the need to follow the rules to protect
themselves against the light after the procedure for 48 hours.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
Physician guideline about TOOKAD should contain the following key elements:</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.9pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
approaches (including VTP with TOOKAD) for the treatment of his prostate cancer
and the potential benefits, risks and uncertainties of VTP with TOOKAD:</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:1.0in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>To
state that information beyond two years after the TOOKAD -VTP procedure is
limited and consequently, data on the long-term efficacy and safety of
TOOKAD-VTP are currently not available</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:1.0in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Information
on the efficacy/safety of any subsequent treatments required, such as radical
prostatectomy, is currently lacking</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Explain
what the VTP procedure involves, including the need to follow the rules to
protect the Patient against light after the procedure for 48 hours, due to the
photosensitising effect of TOOKAD and provide a copy of the TOOKAD Package
Leaflet to the Patient ahead of the VTP procedure</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Explain
what side effects the Patient might expect and the likelihood of him getting
them</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Explain
the procedure as well as relevant efficacy and safety results of TOOKAD with
simple graphics included in the Patient Information Guide.</span></p>

<p class=MsoListParagraph style='margin-left:0in;line-height:normal'><span
lang=EN-GB style='font-size:9.0pt;font-family:"Verdana",sans-serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'>Obligation
to conduct post-authorisation measures</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The MAH
shall complete, within the stated timeframe, the below measures:</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:1.2pt;border-collapse:collapse'>
 <thead>
  <tr>
   <td width=526 valign=top style='width:394.5pt;border:solid black 1.0pt;
   background:white;padding:0in 0in 0in 0in'>
   <p class=MsoNormal style='margin-top:0in;margin-right:5.4pt;margin-bottom:
   0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
   none'><b><span lang=EN-GB style='color:black'>Description</span></b></p>
   </td>
   <td width=103 valign=top style='width:77.3pt;border:solid black 1.0pt;
   border-left:none;background:white;padding:0in 0in 0in 0in'>
   <p class=MsoNormal style='margin-top:0in;margin-right:5.4pt;margin-bottom:
   0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
   none'><b><span lang=EN-GB style='color:black'>Due date</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=526 valign=top style='width:394.5pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:.1pt;margin-bottom:
  0in;margin-left:.1pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB style='font-size:9.0pt;color:black'>P</span><span
  lang=EN-GB style='color:black'>ost-authorisation efficacy study (</span><span
  lang=EN-GB style='font-size:10.0pt;color:black'>PAES): In order to further
  investigate long-term efficacy of TOOKAD and its impact on disease
  progression including potential impact on the efficacy of subsequent radical
  therapy in patients with low risk prostate cancer as well as further
  characterise the long term safety of TOOKAD, the MAH should submit the
  results of a randomised phase 3 study in patients with localised prostate
  cancer compared to active surveillance (7-year follow-up study including in
  an depth biopsy study) (PCM301 FU5).&nbsp; </span></p>
  <p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.3pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:5.4pt;margin-bottom:
  0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB style='color:black'>Submission of final study results:
  31/12/2020</span></p>
  </td>
 </tr>
 <tr>
  <td width=526 valign=top style='width:394.5pt;border:solid black 1.0pt;
  border-top:none;background:white;padding:0in 0in 0in 0in'>
  <p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif;
  color:black'>Post-authorisation efficacy study (PAES): In order to further
  investigate long-term efficacy of TOOKAD and its impact on disease
  progression including potential impact on the efficacy of subsequent radical
  therapy in patients with low risk prostate cancer (excluding very low risk)
  as well as further characterise the long term safety of TOOKAD, the MAH should
  conduct and submit the results of a long-term observational cohort study of
  patients with unilateral low risk localised prostate cancer treated with
  TOOKAD VTP (CLIN1501 PCM401).</span></p>
  </td>
  <td width=103 valign=top style='width:77.3pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:5.4pt;margin-bottom:
  0in;margin-left:5.4pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
  none'><span lang=EN-GB style='color:black'>Submission of final study results:
  31/12/2025</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOO<span
style='letter-spacing:.05pt'>K</span>AD<span style='letter-spacing:-.45pt'> </span><span
style='letter-spacing:.05pt'>18</span>3<span style='letter-spacing:-.1pt'> m</span>g<span
style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt;
background:lightgrey'>powder for solution for injection</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>padeliporfin</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each<span
style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>v</span>ial<span
style='letter-spacing:-.15pt'> </span>co<span style='letter-spacing:.05pt'>n</span>tains<span
style='letter-spacing:-.35pt'> </span>1<span style='letter-spacing:.05pt'>8</span>3<span
style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span
style='letter-spacing:-.1pt'> </span>of<span style='letter-spacing:-.1pt'> </span><span
style='letter-spacing:.05pt'>p</span>a<span style='letter-spacing:.05pt'>d</span>elip<span
style='letter-spacing:.05pt'>o</span>rf<span style='letter-spacing:-.05pt'>i</span>n<span
style='letter-spacing:-.5pt'> </span><span style='letter-spacing:.05pt'>(</span>as<span
style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>d</span>i-p<span
style='letter-spacing:.05pt'>o</span>tassi<span style='letter-spacing:.05pt'>u</span>m<span
style='letter-spacing:-.6pt'> </span>salt).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 mL of
reconstituted solution contains 9.15&nbsp;mg of padeliporfin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='letter-spacing:.05pt'>Ex</span><span lang=EN-GB>cipie<span
style='letter-spacing:.05pt'>n</span>t:<span style='letter-spacing:-.4pt'> </span><span
style='letter-spacing:-.05pt'>M</span>an<span style='letter-spacing:.05pt'>n</span>it<span
style='letter-spacing:.05pt'>o</span>l</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder for
solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Steba<span
style='letter-spacing:-.35pt'> </span>Biotech S.A.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>7 Place<span
style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.05pt'>d</span>u<span
style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.05pt'>T</span><span
style='letter-spacing:-.05pt'>h</span>éâtre</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>L-<span
style='letter-spacing:.05pt'>261</span>3<span style='letter-spacing:-.3pt'> </span>Lu<span
style='letter-spacing:.05pt'>x</span><span style='letter-spacing:-.1pt'>em</span>b<span
style='letter-spacing:.05pt'>o</span>urg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lu<span
style='letter-spacing:.05pt'>x</span>e<span style='letter-spacing:-.1pt'>m</span><span
style='letter-spacing:.05pt'>b</span>o<span style='letter-spacing:.05pt'>u</span>rg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1228/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.       UNIQUE IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.       UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>VIAL</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOO<span
style='letter-spacing:.05pt'>K</span>AD<span style='letter-spacing:-.45pt'> </span><span
style='letter-spacing:.05pt'>18</span>3<span style='letter-spacing:-.1pt'> m</span>g<span
style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt;
background:lightgrey'>powder for solution for injection</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>padeliporfin</span><b><span
lang=EN-GB> </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each<span
style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>v</span>ial<span
style='letter-spacing:-.15pt'> </span>co<span style='letter-spacing:.05pt'>n</span>tains<span
style='letter-spacing:-.35pt'> </span>1<span style='letter-spacing:.05pt'>8</span>3<span
style='letter-spacing:-.05pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span
style='letter-spacing:-.1pt'> </span>of<span style='letter-spacing:-.1pt'> </span><span
style='letter-spacing:.05pt'>p</span>a<span style='letter-spacing:.05pt'>d</span>elip<span
style='letter-spacing:.05pt'>o</span>rf<span style='letter-spacing:-.05pt'>i</span>n<span
style='letter-spacing:-.5pt'> </span><span style='letter-spacing:.05pt'>(</span>as<span
style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.05pt'>d</span>i-p<span
style='letter-spacing:.05pt'>o</span>tassi<span style='letter-spacing:.05pt'>u</span>m<span
style='letter-spacing:-.6pt'> </span>salt).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 mL of
reconstituted solution contains 9.15&nbsp;mg of padeliporfin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='letter-spacing:.05pt'>Ex</span><span lang=EN-GB>cipie<span
style='letter-spacing:.05pt'>n</span>t:<span style='letter-spacing:-.4pt'> </span><span
style='letter-spacing:-.05pt'>M</span>an<span style='letter-spacing:.05pt'>n</span>it<span
style='letter-spacing:.05pt'>o</span>l</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder for
solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Steba<span
style='letter-spacing:-.35pt'> </span>Biotech S.A.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>7 Place<span
style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.05pt'>d</span>u<span
style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.05pt'>T</span><span
style='letter-spacing:-.05pt'>h</span>éâtre</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>L-<span
style='letter-spacing:.05pt'>261</span>3<span style='letter-spacing:-.3pt'> </span>Lu<span
style='letter-spacing:.05pt'>x</span><span style='letter-spacing:-.1pt'>em</span>b<span
style='letter-spacing:.05pt'>o</span>urg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lu<span
style='letter-spacing:.05pt'>x</span>e<span style='letter-spacing:-.1pt'>m</span><span
style='letter-spacing:.05pt'>b</span>o<span style='letter-spacing:.05pt'>u</span>rg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1228/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.       UNIQUE IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.       UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Not applicable.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOO<span
style='letter-spacing:.05pt'>K</span>AD<span style='letter-spacing:-.45pt'> </span><span
style='letter-spacing:.05pt'>366</span><span style='letter-spacing:-.1pt'> m</span>g<span
style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt;
background:lightgrey'>powder for solution for injection</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>padeliporfin</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each<span
style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>v</span>ial<span
style='letter-spacing:-.15pt'> </span>co<span style='letter-spacing:.05pt'>n</span>tains<span
style='letter-spacing:-.35pt'> </span>366<span style='letter-spacing:-.05pt'> </span><span
style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>of<span
style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>p</span>a<span
style='letter-spacing:.05pt'>d</span>elip<span style='letter-spacing:.05pt'>o</span>rf<span
style='letter-spacing:-.05pt'>i</span>n<span style='letter-spacing:-.5pt'> </span><span
style='letter-spacing:.05pt'>(</span>as<span style='letter-spacing:-.15pt'> </span><span
style='letter-spacing:.05pt'>d</span>i-p<span style='letter-spacing:.05pt'>o</span>tassi<span
style='letter-spacing:.05pt'>u</span>m<span style='letter-spacing:-.6pt'> </span>salt).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 mL of
reconstituted solution contains 9.15&nbsp;mg of padeliporfin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='letter-spacing:.05pt'>Ex</span><span lang=EN-GB>cipie<span
style='letter-spacing:.05pt'>n</span>t:<span style='letter-spacing:-.4pt'> </span><span
style='letter-spacing:-.05pt'>M</span>an<span style='letter-spacing:.05pt'>n</span>it<span
style='letter-spacing:.05pt'>o</span>l</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder for
solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 vial</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Steba<span
style='letter-spacing:-.35pt'> </span>Biotech S.A.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>7 Place<span
style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.05pt'>d</span>u<span
style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.05pt'>T</span><span
style='letter-spacing:-.05pt'>h</span>éâtre</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>L-<span
style='letter-spacing:.05pt'>261</span>3<span style='letter-spacing:-.3pt'> </span>Lu<span
style='letter-spacing:.05pt'>x</span><span style='letter-spacing:-.1pt'>em</span>b<span
style='letter-spacing:.05pt'>o</span>urg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lu<span
style='letter-spacing:.05pt'>x</span>e<span style='letter-spacing:-.1pt'>m</span><span
style='letter-spacing:.05pt'>b</span>o<span style='letter-spacing:.05pt'>u</span>rg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1228/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.       UNIQUE IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.       UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PC:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>VIAL</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL
PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOO<span
style='letter-spacing:.05pt'>K</span>AD<span style='letter-spacing:-.45pt'> </span><span
style='letter-spacing:.05pt'>366</span><span style='letter-spacing:-.1pt'> m</span>g<span
style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt;
background:lightgrey'>powder for solution for injection</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>padeliporfin</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each<span
style='letter-spacing:-.2pt'> </span><span style='letter-spacing:.05pt'>v</span>ial<span
style='letter-spacing:-.15pt'> </span>co<span style='letter-spacing:.05pt'>n</span>tains<span
style='letter-spacing:-.35pt'> </span>366<span style='letter-spacing:-.05pt'> </span><span
style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>of<span
style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>p</span>a<span
style='letter-spacing:.05pt'>d</span>elip<span style='letter-spacing:.05pt'>o</span>rf<span
style='letter-spacing:-.05pt'>i</span>n<span style='letter-spacing:-.5pt'> </span><span
style='letter-spacing:.05pt'>(</span>as<span style='letter-spacing:-.15pt'> </span><span
style='letter-spacing:.05pt'>d</span>i-p<span style='letter-spacing:.05pt'>o</span>tassi<span
style='letter-spacing:.05pt'>u</span>m<span style='letter-spacing:-.6pt'> </span>salt).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 mL of
reconstituted solution contains 9.15&nbsp;mg of padeliporfin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='letter-spacing:.05pt'>Ex</span><span lang=EN-GB>cipie<span
style='letter-spacing:.05pt'>n</span>t:<span style='letter-spacing:-.4pt'> </span><span
style='letter-spacing:-.05pt'>M</span>an<span style='letter-spacing:.05pt'>n</span>it<span
style='letter-spacing:.05pt'>o</span>l</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Powder for
solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep the vial in
the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Steba<span
style='letter-spacing:-.35pt'> </span>Biotech S.A.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>7 Place<span
style='letter-spacing:-.3pt'> </span><span style='letter-spacing:.05pt'>d</span>u<span
style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.05pt'>T</span><span
style='letter-spacing:-.05pt'>h</span>éâtre</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>L-<span
style='letter-spacing:.05pt'>261</span>3<span style='letter-spacing:-.3pt'> </span>Lu<span
style='letter-spacing:.05pt'>x</span><span style='letter-spacing:-.1pt'>em</span>b<span
style='letter-spacing:.05pt'>o</span>urg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lu<span
style='letter-spacing:.05pt'>x</span>e<span style='letter-spacing:-.1pt'>m</span><span
style='letter-spacing:.05pt'>b</span>o<span style='letter-spacing:.05pt'>u</span>rg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.     MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/17/1228/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.     INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.       UNIQUE IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.       UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>B. PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>TOOKAD 183 mg powder for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>TOOKAD 366 mg powder for solution for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>padeliporfin</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=21 height=18 id="Image 2"
src="Tookad%204182%20-%20En%20Annexes%20(clean)%20-%20FINAL_files/image003.png"
alt="BT_1000x858px"></span><span lang=EN-GB>This medicine is subject to
additional monitoring. This will allow quick identification of new safety
information. You can help by reporting any side effects you may get. See the
end of section&nbsp;4 for how to report side effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you are given this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse.</span><span lang=EN-GB> This includes any possible
side effects not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.    What TOOKAD is and what it is used for </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.    What you need to know before TOOKAD is used</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.    How TOOKAD is used</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.    Possible side effects </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.    How TOOKAD is stored </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.    Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>1.       What TOOKAD is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>TOOKAD is a medicine that contains padeliporfin (as potassium salt).
It is used to treat adult men who have low&#8209;risk, localised prostate
cancer in only one lobe, using a technique called Vascular&#8209;Targeted
Photodynamic (VTP) therapy. The treatment is carried out under general
anaesthetic (medicines that send you to sleep to prevent pain and discomfort).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Hollow needles are used to insert the fibres into the right place in
the prostate. Once it has been given, TOOKAD has to be activated by laser light
shone along a fibre that targets the light onto the cancer. The activated
medicine then causes the death of the cancer cells.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2.       What you need to know before TOOKAD is used</span></b><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>TOOKAD must not be used if:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You are allergic to padeliporfin or any of
the other ingredients of this medicine (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You have undergone a procedure for treating
benign prostatic hypertrophy including Trans&#8209;Urethral Resection of the
Prostate (TURP).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You are having or have previously had any treatment
for prostate cancer.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You have been diagnosed with a problem with
the liver called cholestasis.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You are having an exacerbation of rectal
inflammatory bowel disease.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You are not able to have general anaesthesia
or invasive procedures. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD should
only be used by personnel trained in the VTP&nbsp;procedure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Talk to your doctor or nurse if: </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You feel any irritation of the skin or
problems with vision or eye irritation after the VTP&nbsp;procedure.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        </span><span lang=EN-GB>You experience
difficulties in getting or maintaining an erection.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You feel any abnormal pain after the VTP&nbsp;procedure.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You have a history of a narrowing of the
urethra or urinary flow problems.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You experience involuntary passing of urine
after the VTP&nbsp;procedure.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You have had an active inflammatory bowel
disease or any condition that may increase the risk of causing abnormal
connection between the rectum and the urethra (recto&#8209;urethral fistula).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You have abnormal blood clotting.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        You have a reduced kidney function or if you
follow a potassium restricted diet.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>To date information beyond two years after VTP procedure is limited
and so, at this time, data are currently not available to know whether the
benefit of TOOKAD-VTP is long-lasting.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you do require further treatment, at the moment, there is limited
information on whether TOOKAD&#8209;VTP affects the efficacy and safety results
of other treatments (such as surgery to remove the prostate or radiotherapy).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Photosensitivity</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Strong light may cause skin reactions and eye discomfort while
TOOKAD is in the blood stream.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For the 48&nbsp;hours after the procedure you should avoid exposure
to direct sunlight (including through windows) and all bright light sources,
both indoors and outdoors. This includes sunbeds, bright computer monitor
screens (see precautions below), and examination lights from medical equipment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Sunscreen creams do not protect you against the type of light (near
infra&#8209;red) that can cause problems after the procedure.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you feel skin or eye discomfort while in hospital, you must tell
your doctor or nurse so the level of lighting can be reduced and extra care can
be taken to protect you from artificial and natural light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>First 12&nbsp;hours after VTP&nbsp;procedure</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>After the procedure, you should wear protective goggles and will be
kept under medical surveillance for at least 6&nbsp;hours in a room with
reduced light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Your medical team will decide if you can leave hospital on the
evening of your treatment. You may need to stay overnight if you have not fully
recovered from the general anaesthetic and depending on your condition.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You must remain under reduced light conditions, without exposing
your skin and your eyes to daylight. Only use light bulbs with a maximum power
of 60&nbsp;watts (for an incandescent light bulb) or 6&nbsp;watts (for LED
lights), or 12&nbsp;watts (for fluorescent low&#8209;energy lights). You may watch
television at a distance of 2&nbsp;metres and, from 6&nbsp;hours after the
procedure, you may use electronic devices such as smartphones, tablets and
computers. In case you need to go out during the day, you must wear protective
clothing and high-protection goggles to shield your skin and eyes.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>12&#8209;48&nbsp;hours after VTP&nbsp;procedure</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You may go outdoors during daylight hours but only in shaded areas
or when it is overcast. You should wear dark clothes and take care to protect
your hands and face from the sun.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>When 48&nbsp;hours have passed after the procedure, you can resume
your normal activities and you can be exposed to direct sunlight.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>No patients with light&#8209;sensitive conditions such as porphyria,
a history of sensitivity to sunlight or a history of photosensitive dermatitis
have received TOOKAD in clinical studies. However, the short duration of action
of TOOKAD means that the risk of enhanced phototoxicity is expected to be low provided
the precautions against light exposure are stricly followed.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There could be
an additional risk of eye photosensitivity in patients who have received intra&#8209;occular
anti&#8209;VEGF (</span><span lang=EN-GB>medicines used to prevent new blood
vessel growth) </span><span lang=EN-GB>therapy. If you have received prior VEGF
therapy, you should take particular care to protect your eyes from light for
48&nbsp;hours post TOOKAD injection. Concomitant use of systemic VEGF
inhibitors is not recommended with TOOKAD.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>See also under “Other medicines and TOOKAD” for photosensitizing
medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Difficulties
in getting or maintaining an erection</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Some difficulties in getting or maintaining an erection is possible
soon after the procedure and may last for more than 6 months.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Risk of damage near the prostate gland</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Because the fibres that carry the light have to be inserted in such
a way that the whole of the lobe of the prostate gland gets exposed, it is
possible that some damage may occur outside of the prostate. Normally this is
just the fat around the prostate and is not important but nearby organs such as
the bladder and rectum may potentially be affected. This is normally avoidable
by careful planning but should it occur there is a risk of an abnormal
connection forming between the rectum and the bladder or skin. This is very
rare.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Problem associated with the urethra</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have a history of a narrowing of the urethra or urinary flow
problems, treatment may increase the risk of poor flow and urinary retention.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Urinary incontinence</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Short&#8209;term urinary incontinence has been observed and may
result from urinary tract infection or from urgency caused by irritation to the
urethra from the procedure. The condition gets better on its own or with
treatment of the infection.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Active inflammatory bowel disease</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have had an active inflammatory bowel disease or any
condition that may increase the risk of causing abnormal connection between the
rectum and the urethra (recto&#8209;urethral fistula), the treatment should be
given only after careful evaluation.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Abnormal clotting</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Patients with abnormal clotting may bleed excessively from the
insertion of the needles required to position the fibres that guide the laser
light. This may also cause bruising, blood in the urine and/or local pain.
Abnormal clotting is not expected to affect how well the treatment works ;
however, it is recommended that drugs that affect clotting are stopped prior to
and for the immediate period following the VTP procedure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>See also under “Other medicines and TOOKAD” for the effects of
anticoagulants and antiplatelet medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Patients on a controlled potassium diet</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine contains potassium. In general, the dose of TOOKAD
contains less than 1&nbsp;mmol</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>(39&nbsp;mg) potassium, i.e. essentially ‘potassium free’. However,
patients weighing more than 115&nbsp;kg will receive more than 1&nbsp;mmol
potassium. This should be taken into consideration by patients with reduced
kidney function or patients on a controlled potassium diet where a rise in
serum potassium would be considered detrimental.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine should not be given to children and adolescents less than
18&nbsp;years of age.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and TOOKAD</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines, including medicines obtained without a
prescription. Some medicines (in particular any medicines that are
photosensitising or that affect blood clotting) may interact with TOOKAD and
should be stopped before using TOOKAD. You may also be required to not take
certain medicines for several days after the VTP&nbsp;procedure. Your doctor
will also advise what medicines may be substituted where appropriate and when
these medicines can be re&#8209;started after the VTP&nbsp;procedure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The following types of medicines may be ones that your doctor will
advise you to stop temporarily:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Medicines with a potentially photosensitising effect:</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Certain antibiotics used to treat infection
(tetracyclines, sulphonamides, quinolones).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Certain medicines used to treat psychiatric
conditions (phenothiazines).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Certain medicines used in type&nbsp;II
diabetes (hypoglycaemic sulphonamides).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Certain medicines used for hypertension,
oedema, heart failure or renal failure (thiazide diuretics).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        A medicine used to treat fungal infections
(griseofulvin).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        A medicine used to treat cardiac arrhythmia
(amiodarone).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>These medicines should be stopped at least 10&nbsp;days before the
procedure with TOOKAD, and for at least 3&nbsp;days after the procedure, or
replaced by other treatments without photosensitising properties. If it is not
possible to stop a photosensitising medicine (such as amiodarone), increased
sensitivity may occur, you may need to protect yourself from direct light
exposure for a longer period.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Anticoagulants (medicines that prevent the blood from clotting)</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>These medicines (e.g. acenocoumarol, warfarin) should be stopped at
least 10&nbsp;days before the VTP procedure with TOOKAD.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Antiplatelet agents (medicines that decrease platelet aggregation
(stickiness) in the blood and reduce clotting)</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>These medicines (e.g. acetylsalicylic acid) should be stopped at
least 10&nbsp;days before the VTP procedure with TOOKAD and re&#8209;started at
least 3&nbsp;days after the procedure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB>Other medicines that may interact with TOOKAD</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The use of medicines such as repaglinide, atorvastatin,
pitavastatin, pravastatin, rosuvastatin, simvastatin, bosentan, glyburide
should be avoided on the day of TOOKAD administration and for at least 24 hours
after administration.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Contraception</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You or your partner or both should use an effective form of birth
control to prevent your partner getting pregnant for 90&nbsp;days after the VTP&nbsp;procedure.
Check with your doctor about the birth control methods to use and how long to
use them for. If your partner becomes pregnant within three months of your
treatment, you must immediately tell your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD is not
indicated for the treatment of women.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>TOOKAD has no influence on the ability to drive or use machines.
However, as the procedure includes general anaesthesia, you should not perform
complex tasks like driving or using machines until 24 hours after a general
anaesthetic is used.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>3.       H</span><span lang=EN-GB>ow TOOKAD is used</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>TOOKAD is restricted to hospital use only. It should only be used by
personnel trained in the VTP&nbsp;procedure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Dose</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The recommended dose of TOOKAD is one single dose of 3.66&nbsp;mg
per kg of body weight, injected into a vein. The injection lasts 10&nbsp;minutes.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For instructions to healthcare professionals on reconstitution of
TOOKAD before injection, see “Reconstitution of the TOOKAD powder for solution
for injection”.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Only the lobe that contains the cancer will be treated. Additional VTP
procedures </span><span lang=EN-GB>of </span><span lang=EN-GB>the prostate are
not recommended.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>VTP procedure</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The day before and at the beginning of the VTP&nbsp;procedure, a
rectal preparation is performed in order to clean the rectum. Your doctor may
prescribe antibiotics to prevent infection and alpha&#8209;blockers (medicines
given to prevent difficulties in urinating). You will be given a general
anaesthetic to send you to sleep before the VTP</span><span lang=EN-GB>&nbsp;procedure.
Fibres to carry the laser light are inserted into the prostate gland by using
hollow needles. TOOKAD is activated immediately after injection by shining
light through the fibres from a connected laser device.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any questions on the use of this medicine, ask your
doctor, your pharmacist or your nurse.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>In addition, inserting needles into the prostate gland and inserting
a urinary catheter for the procedure may be associated with further side
effects.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Possible side effects can occur with TOOKAD and VTP&nbsp;procedure.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>If you get any of the side effects below, <b>tell your doctor
immediately</b>:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Urinary retention (not able to pass urine).
In the few days after the VTP&nbsp;procedure some patients may have
difficulties (poor stream due to urethral narrowing) or inability to pass
urine. This may necessitate inserting a catheter inside your bladder through the
penis and the catheter will remain in place for a few days or weeks to drain
the urine.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Fever, pain and swelling in the area of the
operation might occur after the procedure. These may be signs of infection in
the urinary tract, the prostate or the genital system. In this case, you should
contact your doctor as you may need further blood or urine analysis and
antibiotics treatment. These infections are usually easily treated.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>In addition to the side effects listed previously, other side
effects can occur.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Very common side effects</span></b><span lang=EN-GB> (may affect
more than 1 in 10 people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Problems with or pain on passing urine
(including pain or discomfort on passing urine, bladder pain, the need to pass
urine urgently or more frequently or at night; involuntary passing of urine),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Sexual problems (including difficulty in
getting or maintaining an erection, ejaculation failure, loss of desire or pain
on intercourse),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Blood in the urine (haematuria),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Perineal injury including bruising in the skin,
bruising near where the needles are put into the prostate, pain and tenderness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Genital pain and discomfort (inflammation of
the testicles or the epididymis, pain due to inflammation or fibrosis of the
prostate).</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Common side effects</span></b><span lang=EN-GB> (may affect up to 1
in 10 people)<u> </u></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Anorectal discomfort (discomfort near the
anus and just inside the anus), haemorrhoids (piles), proctalgia (pain in the
anal region),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Problems with bowels (including diarrhoea or
occasional soiling).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        General and musculoskeletal pain (muscle/bony
pain, pain in the end of the limbs, back pain or bleeding into the joints).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Haematospermia (presence of blood in the
ejaculate).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        High blood pressure.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Increases in blood lipids, lactate
dehydrogenase increased, white blood cell increased, creatine phosphokinase
increased, potassium decreased, prostatic specific antigen (PSA) increased.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Skin reaction, erythema (reddening), rash,
dryness, pruritus, depigmentation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Abnormal blood tests related to coagulation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Discomfort in the abdominal region.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Fatigue (tiredness).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>Uncommon side effects</span></b><span lang=EN-GB>
(may affect up to 1 in 100 people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Dizziness, fall,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Headache, </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Sensory disturbance, formication (sensation
like crawling insects on or under the skin).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Eye irritation, photophobia (intolerance to
light).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Dyspnoea exertional (excessive shortness of
breath during or after exercise).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Mood disorder.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Weight decreased. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"TimesNewRoman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you
get any side effects, talk to your doctor or pharmacist or nurse.</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> This
includes any possible side effects not listed in this leaflet.</span><span
lang=EN-GB> </span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>You
can also report side effects directly via </span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;background:lightgrey'>the
national reporting system listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;background:lightgrey'>Appendix
V</span></a></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>.</span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.       How TOOKAD is stored</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You will not have to store this medicine. This medicine is stored
under the responsibility of the specialist. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The following information is intended for the specialist only.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use after the expiry date which is stated on the shield label
after “EXP”. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in a refrigerator (2°C&#8209;8°C).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in the outer carton in order to protect it from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Any unused medicine or waste material should be disposed of in
accordance with local requirements.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What TOOKAD contains </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The </span><span lang=EN-GB>active</span><span
lang=EN-GB> substance is padeliporfin.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>Each
vial of TOOKAD 183 mg contains 183&nbsp;mg of padeliporfin (as potassium salt).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>Each
vial of TOOKAD 366 mg contains 366&nbsp;mg of padeliporfin (as potassium salt).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>          1 mL
of reconstituted solution contains 9.15&nbsp;mg of padeliporfin.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredient is mannitol.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What TOOKAD looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TOOKAD is a dark
powder.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each carton of
TOOKAD 183&nbsp;mg powder for solution for injection contains an amber glass
vial with a blue cap.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each carton of
TOOKAD 366&nbsp;mg powder for solution for injection contains an amber glass
vial with a white cap.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Steba Biotech S.A.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>7
Place du Théâtre</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>L-2613
Luxembourg</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>Luxembourg</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b>Manufacturer</b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>Praxis
Pharmaceutical S.A.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=PT-BR>C/ Hermanos Lumiere 5</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=PT-BR>Parque Tecnologico de Álava (Miñano)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Vitoria-Gasteiz</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>01510 Alava</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Spain</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last </span><span lang=EN-GB>revised in </span></b><b><span
lang=EN-GB>&lt;</span></b><span lang=EN-GB>{<b>MM/YYYY</b>}&gt;</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB>http://www.ema.europa.eu.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The following information is intended for healthcare professionals
only:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Reconstitution of the TOOKAD powder for solution for injection</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The solution must be prepared in a dimmed-light environment due to
the photosensitizing properties of the medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>1.       Reconstitute the solution by adding:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>          - for TOOKAD 183 mg: <b>20&nbsp;mL</b> of a 5&nbsp;% glucose
solution in the vial containing the powder;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>          - for TOOKAD 366 mg: <b>40&nbsp;mL</b> of a 5&nbsp;%
glucose solution in the vial containing the powder.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>2.       Swirl the vial gently for 2&nbsp;minutes. The final
solution concentration is 9.15&nbsp;mg/mL.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>3.       Allow the vial to rest in a vertical position for 3&nbsp;minutes
without further shaking or moving.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>4.       Transfer the contents of the vial into an opaque syringe.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5.       Allow the opaque syringe to rest in a
vertical position for 3&nbsp;minutes to ensure any foam disappears.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>6.       Place a 0.22&nbsp;&#956;m injection filter on the syringe.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>7.       Connect an opaque tube to the filter.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The reconstituted solution for infusion is dark.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Illumination for photoactivation of TOOKAD</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>TOOKAD is locally activated immediately after injection by laser
light at 753&nbsp;nm delivered via interstitial optical fibres from a laser
device at a power of 150&nbsp;mW/cm of fibre, delivering an energy of 200&nbsp;J/cm
over 22&nbsp;minutes 15&nbsp;seconds.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Planning of optical fibre positioning should be performed at the
beginning of the procedure using the treatment guidance software. During the
procedure, the optical fibres are selected and positioned transperineally into
the prostate gland under ultrasound guidance to achieve a Light Density Index
(LDI)&nbsp;&#8805;&nbsp;1 in the targeted tissue.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Storage conditions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in a refrigerator (2°C&#8209;8°C).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep the vial in the outer carton in order to protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>After reconstitution with a 5&nbsp;% glucose solution in its vial,
the chemical and physical stability of TOOKAD has been demonstrated for 8&nbsp;hours
at 15°C&#8209;25°C and at 5°C&nbsp;±&nbsp;3°C. From a microbiological point of
view, the product should be used immediately. If not used immediately, in&#8209;use
storage times and conditions prior to use are the responsibility of the user.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
